Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Maternal serum free ss-hCG and PAPP-A in patients with habitual abortion-influence on first-trimester screening for chromosomal abnormalities.
Abortion, Spontaneous
A correlation analysis between the expression of pregnancy-associated plasma protein A in basal decidual cells and recurrent spontaneous abortion.
Abortion, Spontaneous
Are pregnancy-associated plasma protein-A (PAPP-A) and CA 125 measurements after IVF-ET possible predictors of early pregnancy wastage?
Abortion, Spontaneous
Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study.
Abortion, Spontaneous
Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
Abortion, Spontaneous
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Abortion, Spontaneous
Diagnostic accuracy of maternal serum macrophage inhibitory cytokine-1 and pregnancy-associated plasma protein-A at 6-10 weeks of gestation to predict miscarriage.
Abortion, Spontaneous
Effect of smoking on pregnancy-associated plasma protein A, free beta-human chorionic gonadotropin, and nuchal translucency in the first trimester of pregnancy.
Abortion, Spontaneous
Effects of fetal gender and low first trimester aneuploidy screening markers on preterm birth.
Abortion, Spontaneous
Fetal loss after chorionic villus sampling in twin pregnancy.
Abortion, Spontaneous
First trimester combined screening test for aneuploidies in anti-Ro carriers pregnant women.
Abortion, Spontaneous
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
Abortion, Spontaneous
First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome?
Abortion, Spontaneous
First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss.
Abortion, Spontaneous
First-trimester serum PAPP-A and f?-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome.
Abortion, Spontaneous
Low levels of pregnancy-associated plasma protein-A in asymptomatic women destined for miscarriage.
Abortion, Spontaneous
Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes.
Abortion, Spontaneous
Low pregnancy-associated plasma protein-a at 10(+1) to 14(+6) weeks of gestation and a possible mechanism leading to miscarriage.
Abortion, Spontaneous
Maternal level of pregnancy-associated plasma protein A as a predictor of pregnancy failure in threatened abortion.
Abortion, Spontaneous
Measurements of placental, decidual, and fetal proteins before and after chorionic villus sampling.
Abortion, Spontaneous
Predictive value of pregnancy-associated plasma protein-A in relation to fetal loss: A systematic review and meta-analysis.
Abortion, Spontaneous
Pregnancy-associated plasma protein A, free human chorionic gonadotrophin and nuchal translucency as predictors of miscarriage.
Abortion, Spontaneous
Prenatal diagnosis of partial monosomy 2q (2q37.3?qter) and partial trisomy 10q (10q24.31?qter) of paternal origin associated with increased nuchal translucency and abnormal maternal serum screening results.
Abortion, Spontaneous
Procedure-Related Fetal Loss following Chorionic Villus Sampling after First-Trimester Aneuploidy Screening.
Abortion, Spontaneous
Progesterone dependence and extratrophoblastic origin of pregnancy-associated plasma protein-A (PAPP-A) in early pregnancy.
Abortion, Spontaneous
The risk of adverse pregnancy outcome among pregnancies with extremely low maternal PAPP-A.
Abortion, Spontaneous
The value of vascular endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages.
Abortion, Spontaneous
Ultrasound and circulating placental protein measurements in complications of early pregnancy.
Abortion, Threatened
Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
Abortion, Threatened
First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome?
Abortion, Threatened
Maternal level of pregnancy-associated plasma protein A as a predictor of pregnancy failure in threatened abortion.
Abortion, Threatened
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Abortion, Threatened
Pregnancy-associated protein-A does not improve predictability of pregnancy success or failure over human chorionic gonadotropin levels in early normal and abnormal pregnancy.
Abortion, Threatened
Value of Schwangerschaftsprotein 1 (SP1) and pregnancy-associated plasma protein-A (PAPP-A) in the clinical management of threatened abortion.
Abruptio Placentae
Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption.
Abruptio Placentae
First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis.
Abruptio Placentae
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
Abruptio Placentae
Obstetric Outcome in Pregnant Patients with Low Level of Pregnancy-Associated Plasma Protein A in First Trimester.
Abruptio Placentae
Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.
Abruptio Placentae
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation.
Acute Coronary Syndrome
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Acute Coronary Syndrome
Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome.
Acute Coronary Syndrome
Association of calcium channel blocker use and pregnancy-associated plasma protein-A among older adults with hypertension: results from the ilSIRENTE study.
Acute Coronary Syndrome
Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study.
Acute Coronary Syndrome
Changes of pregnancy-associated plasma protein-A in patients with acute coronary syndrome.
Acute Coronary Syndrome
Cigarette Smoking Increases Pregnancy-associated Plasma Protein-A in Men.
Acute Coronary Syndrome
Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation.
Acute Coronary Syndrome
Comment on immunoassays developed for pregnancy-associated plasma protein-A (PAPP-A) in pregnancy may not recognize PAPP-A in acute coronary syndromes.
Acute Coronary Syndrome
Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients.
Acute Coronary Syndrome
Development of a sensitive and specific immunological test for detecting pregnancy-associated plasma protein A in patients with acute coronary syndrome.
Acute Coronary Syndrome
Effect of routine heparins treatment in acute coronary syndrome on serum pregnancy-associated plasma protein a concentration.
Acute Coronary Syndrome
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Acute Coronary Syndrome
Elevated Serum Free Pregnancy-Associated Plasma Protein-A Independently Predicts Mortality in Haemodialysis Patients but Is Not Associated with Recurrent Haemodialysis-Induced Ischaemic Myocardial Injury.
Acute Coronary Syndrome
Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patients.
Acute Coronary Syndrome
Evaluation of Serum Pregnancy Associated Plasma Protein-A & Plasma D-Dimer in Acute Coronary Syndrome.
Acute Coronary Syndrome
Examination of serum pregnancy-associated plasma protein A clinical value in acute coronary syndrome prediction and monitoring.
Acute Coronary Syndrome
Free vs Total Pregnancy-Associated Plasma Protein A (PAPP-A) as a Predictor of 1-Year Outcome in Patients Presenting with Non-ST-Elevation Acute Coronary Syndrome.
Acute Coronary Syndrome
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Acute Coronary Syndrome
Growth differentiation factor 15, ischemia modified albumin and pregnancy-associated plasma protein A in patients with coronary artery disease.
Acute Coronary Syndrome
High positive predictive value of PAPP-A for acute coronary syndrome diagnosis in heparin-naïve patients.
Acute Coronary Syndrome
Immunoassays developed for pregnancy-associated plasma protein-A (PAPP-A) in pregnancy may not recognize PAPP-A in acute coronary syndromes.
Acute Coronary Syndrome
Immunofluorometric point-of-care assays for the detection of acute coronary syndrome-related noncomplexed pregnancy-associated plasma protein A.
Acute Coronary Syndrome
Increased levels of pregnancy-associated plasma protein A are associated with mortality in hemodialysis patients: preliminary results.
Acute Coronary Syndrome
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Acute Coronary Syndrome
Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study.
Acute Coronary Syndrome
Influence of concomitant heparin administration on pregnancy-associated plasma protein-A levels in acute coronary syndrome with ST segment elevation.
Acute Coronary Syndrome
Interplay between PAPP-A, inflammation and adiposity in patients with angiographically proven acute coronary syndrome (ACS).
Acute Coronary Syndrome
Intravenous Administration of Low Molecular Weight and Unfractionated Heparin Elicits a Rapid Increase in Serum Pregnancy-Associated Plasma Protein A.
Acute Coronary Syndrome
Level of Pregnancy-associated Plasma Protein-A Correlates With Coronary Thin-cap Fibroatheroma Burden in Patients With Coronary Artery Disease: Novel Findings From 3-Vessel Virtual Histology Intravascular Ultrasound Assessment.
Acute Coronary Syndrome
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Acute Coronary Syndrome
Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction.
Acute Coronary Syndrome
Long-term prognostic utility of PAPP-A and calprotectin in suspected acute coronary syndrome.
Acute Coronary Syndrome
Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy.
Acute Coronary Syndrome
Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.
Acute Coronary Syndrome
Novel biomarkers for cardiovascular risk prediction.
Acute Coronary Syndrome
Novel markers in the acute coronary syndrome: BNP, IL-6, PAPP-A.
Acute Coronary Syndrome
Optimisation of sandwich ELISA based on monoclonal antibodies for the specific measurement of pregnancy-associated plasma protein (PAPP-A) in acute coronary syndrome.
Acute Coronary Syndrome
PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI.
Acute Coronary Syndrome
PAPP-A in cardiac and non-cardiac conditions.
Acute Coronary Syndrome
PAPP-A: a marker of plaque instability. Is it ready for prime time?
Acute Coronary Syndrome
Positive correlation between pregnancy-associated plasma protein-A level and OX40 ligand expression in patients with acute coronary syndromes.
Acute Coronary Syndrome
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
Acute Coronary Syndrome
Pregnancy associated plasma protein-A (PAPP-A) as an early marker for the diagnosis of acute coronary syndrome.
Acute Coronary Syndrome
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Acute Coronary Syndrome
Pregnancy associated plasma protein-A and risk stratification of patients presenting with chest pain in the emergency department.
Acute Coronary Syndrome
Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.
Acute Coronary Syndrome
Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A and procalcitonin as markers of myocardial injury in patients with acute coronary syndrome.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Acute Coronary Syndrome
Pregnancy-associated plasma protein a as predictor of outcome in patients with suspected acute coronary syndromes.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A during hemodialysis with polyamide and diacetate cellulosic membranes.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A in dialysis patients.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A in non-cardiac conditions.
Acute Coronary Syndrome
Pregnancy-Associated Plasma Protein A Induces Inflammatory Cytokine Expression by Activating IGF-I/PI3K/Akt Pathways.
Acute Coronary Syndrome
Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI).
Acute Coronary Syndrome
Pregnancy-associated plasma protein predicts outcomes of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A and acute coronary syndromes: cause or consequence?
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A and the vulnerable plaque.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt-NF-?B axis.
Acute Coronary Syndrome
Pregnancy-associated plasma protein-a, a marker for outcome in patients suspected for acute coronary syndrome.
Acute Coronary Syndrome
Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events.
Acute Coronary Syndrome
Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris.
Acute Coronary Syndrome
Prognostic Value of Ultra-sensitive Pregnancy Associated Plasma Protein-A in Patients with Acute Coronary Syndorme.
Acute Coronary Syndrome
Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.
Acute Coronary Syndrome
Relationship between Pregnancy-associated Plasma Protein-A and tissue factor levels in the coronary circulation of patients with acute coronary syndrome.
Acute Coronary Syndrome
Relative value of serum pregnancy-associated plasma protein A (PAPP-A) and GRACE score for a 1-year prognostication: A complement to calculation in patients with suspected acute coronary syndrome.
Acute Coronary Syndrome
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
Acute Coronary Syndrome
Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration.
Acute Coronary Syndrome
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
Acute Coronary Syndrome
The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease.
Acute Coronary Syndrome
Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome.
Acute Coronary Syndrome
[Acute coronary syndrome and inflammation. Biomarkers for diagnostics and risk stratification]
Acute Coronary Syndrome
[Changes of plasma CD40L and PAPP-A in patients with acute coronary syndrome after the PCI operation]
Acute Coronary Syndrome
[Effect of angiotensin II on pregnancy-associated plasma protein A and insulin-like growth factor 1 gene expression in human umbilical artery smooth muscle cells]
Acute Coronary Syndrome
[Effects of C-reactive protein and tumor necrosis factor-alpha on mRNA expression of pregnancy-associated plasma protein-A in monocytes]
Acute Coronary Syndrome
[Expression of COX-2 and pregnancy associate plasma protein A in coronary arteries and their relationship with acute coronary syndrome: an autopsy study of 42 cases]
Acute Coronary Syndrome
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Acute Coronary Syndrome
[Meta-analysis on the prognostic value of pregnancy-associated plasma protein-A in acute coronary syndrome].
Acute Kidney Injury
Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Adenocarcinoma
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
Adenoma
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Adenomyosis
Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis.
Alzheimer Disease
Using redescription mining to relate clinical and biological characteristics of cognitively impaired and Alzheimer's disease patients.
Anaphylaxis
Distinct plasma biomarkers confirm the diagnosis of mastocytosis and identify increased risk of anaphylaxis.
Anemia
Human chorionic gonadotropin and plasma protein-A in alpha0-thalassemia pregnancies.
Anemia, Sickle Cell
Does first-trimester serum pregnancy-associated plasma protein A differ in pregnant women with sickle cell disease?
Angina Pectoris
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
Angina, Stable
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Angina, Stable
Level of Pregnancy-associated Plasma Protein-A Correlates With Coronary Thin-cap Fibroatheroma Burden in Patients With Coronary Artery Disease: Novel Findings From 3-Vessel Virtual Histology Intravascular Ultrasound Assessment.
Angina, Stable
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Angina, Stable
Measurement and clinical significance of circulating PAPP-A in ACS patients.
Angina, Stable
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Angina, Stable
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Angina, Stable
Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris.
Angina, Stable
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.
Angina, Stable
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
Angina, Stable
The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease.
Angina, Stable
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Angina, Unstable
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Angina, Unstable
Biomarkers for early detection of risk in female patients with coronary artery disease: pilot study.
Angina, Unstable
Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.
Angina, Unstable
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Angina, Unstable
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
Angina, Unstable
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Angina, Unstable
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Angina, Unstable
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Angina, Unstable
Pregnancy-associated plasma protein-A as a marker of culprit lesion instability in unstable angina patients: an intravascular ultrasound study.
Angina, Unstable
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
Angina, Unstable
[Evaluation on the relationship between pregnancy associated plasma protein-a and intravascular ultrasound detected culprit coronary plaque morphology in patients with unstable angina].
Angina, Unstable
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Angina, Unstable
[Placenta associated plasma protein-A (PAPP-A): clinical value in cardiovascular medicine]
Aortic Valve Stenosis
The relationship between serum pregnancy-associated plasma protein-A level in patients with aortic valve stenosis: a case-control study.
Asthma
Does pregnancy-associated plasma protein A have a role in allergic rhinitis?
Asthma
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Asthma
Pregnancy-associated plasma protein-A (PAPP-A) levels in patients with severe allergic asthma are reduced by omalizumab.
Asthma
Pregnancy-associated plasma protein-A and asthma.
Atherosclerosis
A coronary proatherosclerotic marker: Pregnancy-associated plasma protein A and its association with coronary calcium score and carotid intima-media thickness.
Atherosclerosis
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Atherosclerosis
Can pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?
Atherosclerosis
Effects of mutated pregnancy-associated plasma protein-a on atherosclerotic lesion development in mice.
Atherosclerosis
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Atherosclerosis
Elevated serum levels of pregnancy-associated plasma protein-A in type 2 diabetics compared to healthy controls: associations with subclinical atherosclerosis parameters.
Atherosclerosis
Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients.
Atherosclerosis
Evaluation of Serum Pregnancy Associated Plasma Protein-A & Plasma D-Dimer in Acute Coronary Syndrome.
Atherosclerosis
Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet.
Atherosclerosis
Hsa-circ_0010283 Regulates Oxidized Low-Density Lipoprotein-Induced Proliferation and Migration of Vascular Smooth Muscle Cells by Targeting the miR-133a-3p/Pregnancy-Associated Plasma Protein A Axis.
Atherosclerosis
Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency.
Atherosclerosis
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Atherosclerosis
Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study.
Atherosclerosis
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
Atherosclerosis
LncRNA XIST regulates atherosclerosis progression in ox-LDL-induced HUVECs.
Atherosclerosis
MiR-182-5p Inhibits the Proliferation of Vascular Smooth Muscle Cells Induced by ox-LDL Through Targeting PAPPA.
Atherosclerosis
Motor and memory testing of long-lived pregnancy-associated plasma protein--a knock-out mice.
Atherosclerosis
Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.
Atherosclerosis
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Atherosclerosis
PAPP-A and the IGF system in Atherosclerosis - What's Up, What's Down?
Atherosclerosis
PAPP-A in cardiac and non-cardiac conditions.
Atherosclerosis
PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXR? through the IGF-I-mediated signaling pathway.
Atherosclerosis
Pregnancy associated plasma protein-A (PAPP-A) as an early marker for the diagnosis of acute coronary syndrome.
Atherosclerosis
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Atherosclerosis
Pregnancy-associated plasma protein A (PAPP-A) in obese children: relation to markers and risk factors of atherosclerosis, and members of the IGF system.
Atherosclerosis
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Atherosclerosis
Pregnancy-Associated Plasma Protein A Induces Inflammatory Cytokine Expression by Activating IGF-I/PI3K/Akt Pathways.
Atherosclerosis
Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease.
Atherosclerosis
Pregnancy-Associated Plasma Protein-A Accelerates Atherosclerosis by Regulating Reverse Cholesterol Transport and Inflammation.
Atherosclerosis
Pregnancy-associated plasma protein-A as a marker for long-term mortality in patients with peripheral atherosclerosis: inconclusive findings from the Linz Peripheral Arterial Disease (LIPAD) study.
Atherosclerosis
Pregnancy-associated plasma protein-A in atherosclerosis: Molecular marker, mechanistic insight, and therapeutic target.
Atherosclerosis
Pregnancy-associated plasma protein-a is associated with subclinical atherosclerosis in men with HIV infection.
Atherosclerosis
Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation.
Atherosclerosis
Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt-NF-?B axis.
Atherosclerosis
Pregnancy-associated plasma protein-A: an emerging cardiac biomarker.
Atherosclerosis
Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk.
Atherosclerosis
Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
Atherosclerosis
Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling.
Atherosclerosis
Surface association of pregnancy-associated plasma protein-A accounts for its colocalization with activated macrophages.
Atherosclerosis
Targeted Inhibition of Pregnancy-Associated Plasma Protein-A Activity Reduces Atherosclerotic Plaque Burden in Mice.
Atherosclerosis
Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion development.
Atherosclerosis
[Association between IGF system and PAPP-A in coronary atherosclerosis].
Atherosclerosis
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
Atherosclerosis
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Atherosclerosis
[The carotid drainage system--a "window" into the atherosclerosis process in diabetics?]
Blood Group Incompatibility
Non-invasive fetal RHD genotyping in the first trimester of pregnancy.
Bone Diseases, Metabolic
Impact of pregnancy-associated plasma protein-a deletion on the adult murine skeleton.
Bone Diseases, Metabolic
The metalloproteinase Papp-aa controls epithelial cell quiescence-proliferation transition.
Breast Neoplasms
Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes.
Breast Neoplasms
Collagen and PAPP-A in the Etiology of Postpartum Breast Cancer.
Breast Neoplasms
Expression of haptoglobin-related protein and its potential role as a tumor antigen.
Breast Neoplasms
Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.
Breast Neoplasms
Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Breast Neoplasms
Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer.
Breast Neoplasms
Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
Breast Neoplasms
Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
Breast Neoplasms
Pregnancy-associated plasma protein-A expression in human breast cancer.
Breast Neoplasms
Pregnancy-Associated Plasma Protein-A, Alpha-2-Macroglobulin, Pregnancy Zone Protein and Their Complexes with IgG in Sera of Healthy Non-Pregnant and Pregnant Woman, and Patients with Breast Cancer.
Breast Neoplasms
Prenatal Biochemical Screening and a Woman's Long-Term Risk of Cancer: A Population-Based Cohort Study.
Breast Neoplasms
Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study.
Breast Neoplasms
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
Breast Neoplasms
The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning.
Breast Neoplasms
The Non-coding Mammary Carcinoma Susceptibility Locus, Mcs5c, Regulates Pappa Expression via Age-Specific Chromatin Folding and Allele-Dependent DNA Methylation.
Breech Presentation
First trimester PAPP-A MoM values predictive for breech presentation at term of pregnancy.
Carcinogenesis
Lactation opposes pappalysin-1-driven pregnancy-associated breast cancer.
Carcinogenesis
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Carcinoma
Overexpression of pregnancy-associated plasma protein-a in ovarian cancer cells promotes tumor growth in vivo.
Carcinoma
PAPP-A functions as a tumor suppressor and is downregulated in renal cell carcinoma.
Carcinoma
PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma.
Carcinoma
Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Carcinoma
Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
Carcinoma
The Non-coding Mammary Carcinoma Susceptibility Locus, Mcs5c, Regulates Pappa Expression via Age-Specific Chromatin Folding and Allele-Dependent DNA Methylation.
Carcinoma
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Carcinoma, Hepatocellular
Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NF?B Signaling in Hepatocellular Carcinoma.
Carcinoma, Ovarian Epithelial
[Expression and activity of proteases in metastasis of ovarian cancer].
Carcinoma, Renal Cell
PAPP-A functions as a tumor suppressor and is downregulated in renal cell carcinoma.
Carcinoma, Renal Cell
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Cardiomyopathies
Comparative gene expression and phenotype analyses of skeletal muscle from aged wild-type and PAPP-A-deficient mice.
Cardiovascular Diseases
A combination of plaque components analyzed by integrated backscatter intravascular ultrasound (IB-IVUS) and serum pregnancy-associated plasma protein A (PAPP-A) levels predict the no-reflow phenomenon during percutaneous coronary intervention (PCI).
Cardiovascular Diseases
Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease.
Cardiovascular Diseases
Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease.
Cardiovascular Diseases
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
Cardiovascular Diseases
Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients.
Cardiovascular Diseases
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Cardiovascular Diseases
Giant magnetoresistive-based biosensing probe station system for multiplex protein assays.
Cardiovascular Diseases
IGFBP-4 and PAPP-A in normal physiology and disease.
Cardiovascular Diseases
Inducible reduction in pregnancy-associated plasma protein-a gene expression inhibits established atherosclerotic plaque progression in mice.
Cardiovascular Diseases
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
Cardiovascular Diseases
Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.
Cardiovascular Diseases
Local IGF Bioactivity Associates with High PAPP-A Activity in the Pericardial Cavity of Cardiovascular Disease Patients.
Cardiovascular Diseases
Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) - intra- and inter-individual variability in chronic hemodialysis patients.
Cardiovascular Diseases
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Cardiovascular Diseases
Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: Use of a new monoclonal antibody-based assay.
Cardiovascular Diseases
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Cardiovascular Diseases
Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease.
Cardiovascular Diseases
Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches.
Cardiovascular Diseases
Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis.
Cardiovascular Diseases
Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation.
Cardiovascular Diseases
Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt-NF-?B axis.
Cardiovascular Diseases
Targeted Inhibition of Pregnancy-Associated Plasma Protein-A Activity Reduces Atherosclerotic Plaque Burden in Mice.
Cardiovascular Diseases
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
Carotid Artery Diseases
Association of E-Selectin Gene Polymorphism and Serum PAPP-A with Carotid Atherosclerosis in End-Stage Renal Disease.
Carotid Artery Diseases
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Carotid Artery Diseases
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Carotid Artery Diseases
Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events.
Cerebrovascular Disorders
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Cerebrovascular Disorders
Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease.
Cerebrovascular Disorders
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Cerebrovascular Disorders
Profile of serum pregnancy-associated plasma protein a after sustained subcutaneous low molecular weight heparin administration in patients with cerebrovascular diseases.
Cholestasis
Pregnancy-associated plasma protein a levels are decreased in obstetric cholestasis.
Cholestasis, Intrahepatic
First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy.
Chromosome Disorders
Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A.
Chronic Kidney Disease-Mineral and Bone Disorder
Pregnancy-associated plasma protein A in dialysis patients.
Confusion
Prognostic value of serum pregnancy-associated plasma protein A level at the initial ED presentation in elderly patients with CAP.
Congenital Abnormalities
Assessment of ?-human-derived chorionic gonadotrophic hormone (?hCG) and pregnancy-associated plasma protein A (PAPP-A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: a cohort study.
Congenital Abnormalities
The utility of pregnancy associated plasma protein-A MoM values in prediction of term respiratory distress syndrome.
Congenital Abnormalities
Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes.
Congenital Abnormalities
Whole-exome sequencing for diagnosis of Peters-plus syndrome after prenatal diagnosis of recurrent low PAPP-A and multiple fetal anomalies in two consecutive pregnancies.
Coronary Artery Disease
A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity.
Coronary Artery Disease
Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease.
Coronary Artery Disease
Growth differentiation factor 15, ischemia modified albumin and pregnancy-associated plasma protein A in patients with coronary artery disease.
Coronary Artery Disease
Level of Pregnancy-associated Plasma Protein-A Correlates With Coronary Thin-cap Fibroatheroma Burden in Patients With Coronary Artery Disease: Novel Findings From 3-Vessel Virtual Histology Intravascular Ultrasound Assessment.
Coronary Artery Disease
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Coronary Artery Disease
Measurement and clinical significance of circulating PAPP-A in ACS patients.
Coronary Artery Disease
MiR-182-5p Inhibits the Proliferation of Vascular Smooth Muscle Cells Induced by ox-LDL Through Targeting PAPPA.
Coronary Artery Disease
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Coronary Artery Disease
Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe?
Coronary Artery Disease
Pregnancy associated plasma protein-A and risk stratification of patients presenting with chest pain in the emergency department.
Coronary Artery Disease
Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.
Coronary Artery Disease
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Coronary Artery Disease
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Coronary Artery Disease
Pregnancy-associated plasma protein A and proform eosinophilic major basic protein in the detection of different types of coronary artery disease.
Coronary Artery Disease
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Coronary Artery Disease
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Coronary Artery Disease
Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease.
Coronary Artery Disease
Pregnancy-associated plasma protein-A in atherosclerosis: Molecular marker, mechanistic insight, and therapeutic target.
Coronary Artery Disease
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Coronary Artery Disease
Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis.
Coronary Artery Disease
Pregnancy-Associated Plasma Protein-A Levels in Individuals with and without Coronary Artery Disease.
Coronary Artery Disease
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina.
Coronary Artery Disease
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.
Coronary Artery Disease
Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling.
Coronary Artery Disease
The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease.
Coronary Disease
Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease.
Coronary Disease
Positive correlation between pregnancy-associated plasma protein-A level and OX40 ligand expression in patients with acute coronary syndromes.
Coronary Disease
Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.
Coronary Disease
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Coronary Disease
Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease.
Coronary Disease
Pregnancy-associated plasma protein A in non-cardiac conditions.
Coronary Disease
Pregnancy-associated plasma protein A predicts adverse vascular events in patients with coronary heart disease: a systematic review and meta-analysis.
Coronary Disease
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Coronary Disease
Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Coronary Disease
THE ROLE OF LIPOPROTEIN (A) AND PREGNANCY ASSOCIATED PLASMA PROTEIN A IN DIAGNOSTICS CORONARY HEART DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
Coronary Disease
[Laboratory diagnosis of atherosclerotic plaque damage in patients with coronary heart disease: PAPP-A (a review of literature)].
Coronary Disease
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Coronary Stenosis
Positive correlation between pregnancy-associated plasma protein-A level and OX40 ligand expression in patients with acute coronary syndromes.
Coronary Stenosis
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Coronary Stenosis
Pregnancy-associated plasma protein predicts outcomes of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome.
Coronary Stenosis
Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris.
Craniosynostoses
Prenatal diagnosis and molecular cytogenetic characterization of de novo pure partial trisomy 6p associated with microcephaly, craniosynostosis and abnormal maternal serum biochemistry.
Cysts
Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle.
Cysts
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
De Lange Syndrome
Assignment of the human gene for pregnancy-associated plasma protein A (PAPPA) to 9q33.1 by fluorescence in situ hybridization to mitotic and meiotic chromosomes.
De Lange Syndrome
Low first-trimester pregnancy-associated plasma protein-A and Cornelia de Lange syndrome.
De Lange Syndrome
Pregnancy-associated plasma protein A: a possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndrome.
De Lange Syndrome
Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies.
Death, Sudden, Cardiac
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Decompression Sickness
Papp-a2 modulates development of cranial cartilage and angiogenesis in zebrafish embryos.
Dementia
Using redescription mining to relate clinical and biological characteristics of cognitively impaired and Alzheimer's disease patients.
Developmental Dysplasia of the Hip
Association of a single nucleotide polymorphism in pregnancy-associated plasma protein-A2 with developmental dysplasia of the hip: a case-control study.
Developmental Dysplasia of the Hip
Expression of PAPP-A2 and IGF Pathway-Related Proteins in the Hip Joint of Normal Rat and Those with Developmental Dysplasia of the Hip.
Diabetes Mellitus
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Diabetes Mellitus
Association between pregnancy-associated plasma protein-A levels in the first trimester and gestational diabetes mellitus in Chinese women.
Diabetes Mellitus
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Diabetes Mellitus
First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus.
Diabetes Mellitus
First trimester maternal serum free ?-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
Diabetes Mellitus
First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring.
Diabetes Mellitus
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Diabetes Mellitus
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Diabetes Mellitus
Impact of type 1 diabetes and glycemic control on fetal aneuploidy biochemical markers.
Diabetes Mellitus
Placental and circulating pregnancy-associated plasma protein A concentrates in normal and pathological term pregnancies.
Diabetes Mellitus
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Diabetes Mellitus
Pregnancy-associated plasma protein A and mortality in haemodialysis.
Diabetes Mellitus
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Diabetes Mellitus
Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus.
Diabetes Mellitus
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Diabetes Mellitus
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Diabetes Mellitus
Temporal Effect of Afro-Caribbean Race on Serum Pregnancy-Associated Plasma Protein-A at 9-13 Weeks' Gestation in Screening for Aneuploidies.
Diabetes Mellitus
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Diabetes Mellitus, Type 1
A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Diabetes Mellitus, Type 1
Impact of type 1 diabetes and glycemic control on fetal aneuploidy biochemical markers.
Diabetes Mellitus, Type 1
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Diabetes Mellitus, Type 2
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Diabetes Mellitus, Type 2
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Diabetes Mellitus, Type 2
Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A.
Diabetes Mellitus, Type 2
PAPP-A activity is increased in cerebrospinal fluid from patients with diabetic polyneuropathy and correlates with peripheral nerve impairment.
Diabetes Mellitus, Type 2
Pregnancy-associated plasma protein-a levels are related to glycemic control but not to lipid profile or hemostatic parameters in type 2 diabetes.
Diabetes, Gestational
Association between pregnancy-associated plasma protein-A and gestational diabetes requiring insulin treatment at 11-14 weeks of gestation.
Diabetes, Gestational
Association between pregnancy-associated plasma protein-A levels in the first trimester and gestational diabetes mellitus in Chinese women.
Diabetes, Gestational
Can first-trimester screening program detect women at high risk for gestational diabetes mellitus?
Diabetes, Gestational
Early Pregnancy-Associated Plasma Protein A Concentrations are Associated with Third Trimester Insulin Sensitivity.
Diabetes, Gestational
Evaluation of maternal and perinatal outcomes among overweight women who experienced stillbirth.
Diabetes, Gestational
First Trimester Combined Test (FTCT) as a Predictor of Gestational Diabetes Mellitus.
Diabetes, Gestational
First trimester maternal serum free ?-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
Diabetes, Gestational
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
Diabetes, Gestational
First trimester pregnancy-associated plasma protein-A in pregnancies complicated by subsequent gestational diabetes.
Diabetes, Gestational
First trimesters Pregnancy-Associated Plasma Protein-A levels value to Predict Gestational diabetes Mellitus: A systematic review and meta-analysis of the literature.
Diabetes, Gestational
First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus.
Diabetes, Gestational
Gestational diabetes mellitus and first trimester pregnancy-associated plasma protein A: A case-control study in a Chinese population.
Diabetes, Gestational
Gestational diabetes mellitus: including serum pregnancy-associated plasma protein-A testing in the clinical management of primiparous women? A case-control study.
Diabetes, Gestational
Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A.
Diabetes, Gestational
Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study.
Diabetes, Gestational
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Diabetes, Gestational
PAPP-A concentrations change in patients with gestational diabetes.
Diabetes, Gestational
Potential role of biochemical placentation markers - pregnancy associated plasma protein-A and human chorionic gonadotropin for early gestational diabetes screening - a pilot study.
Diabetes, Gestational
Prediction of Gestational Diabetes by Measuring the Levels of Pregnancy Associated Plasma Protein-A (PAPP-A) During Gestation Weeks 11-14.
Diabetes, Gestational
Pregnancy-associated plasma protein-A2 levels are increased in early-pregnancy gestational diabetes: a novel biomarker for early risk estimation.
Diabetes, Gestational
Studies on the concentration of pregnancy-associated plasma protein-A during normal and complicated pregnancy.
Diabetes, Gestational
Study on the correlation and predictive value of serum pregnancy-associated plasma protein A, triglyceride and serum 25-hydroxyvitamin D levels with gestational diabetes mellitus.
Diabetes, Gestational
Temporal Variation in Soluble Human Leukocyte Antigen-G (sHLA-G) and Pregnancy-Associated Plasma Protein A (PAPP-A) in Pregnancies Complicated by Gestational Diabetes Mellitus and in Controls.
Diabetes, Gestational
The association between gestational diabetes mellitus and first trimester aneuploidy screening markers.
Diabetes, Gestational
The Immunosignature of Mother/Fetus Couples in Gestational Diabetes Mellitus: Role of HLA-G 14?bp ins/del and PAPP-A A/C Polymorphisms in the Uterine Inflammatory Milieu.
Diabetes, Gestational
Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study.
Diabetic Nephropathies
Mice deficient in PAPP-A show resistance to the development of diabetic nephropathy.
Diabetic Nephropathies
Motor and memory testing of long-lived pregnancy-associated plasma protein--a knock-out mice.
Diabetic Nephropathies
PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.
Diabetic Nephropathies
Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study.
Diabetic Neuropathies
PAPP-A activity is increased in cerebrospinal fluid from patients with diabetic polyneuropathy and correlates with peripheral nerve impairment.
Down Syndrome
A First-Trimester Biomarker Panel for Predicting the Development of Gestational Diabetes.
Down Syndrome
A re-assessment of biochemical marker distributions in T21 affected and unaffected twin pregnancies in the first trimester.
Down Syndrome
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Down Syndrome
A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies.
Down Syndrome
ACOG Committee Opinion #296: first-trimester screening for fetal aneuploidy.
Down Syndrome
Additional performance of nasal bone in first trimester screening.
Down Syndrome
Additive effect of factors related to assisted conception on the reduction of maternal serum PAPP-A concentrations and the increased false-positive rates in first-trimester Down syndrome screening.
Down Syndrome
Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions.
Down Syndrome
Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A.
Down Syndrome
Aneuploidy screening in the first trimester.
Down Syndrome
Appropriate biochemical parameters in first-trimester screening for Down syndrome.
Down Syndrome
Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks?
Down Syndrome
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Down Syndrome
Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome.
Down Syndrome
Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
Down Syndrome
Autocorrelation and cross-correlation between hCG? and PAPP-A in repeated sampling during first trimester of pregnancy.
Down Syndrome
Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited.
Down Syndrome
Biochemical markers of trisomy 21 and the pathophysiology of Down's syndrome pregnancies.
Down Syndrome
Biological variation of free ? chorionic gonadotropin and pregnancy-associated plasma protein A in first trimester pregnancies.
Down Syndrome
Combined first-trimester Down syndrome screening in HIV-infected women.
Down Syndrome
Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Down Syndrome
Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.
Down Syndrome
Comparing first trimester screening performance: routine care gynaecologists' practices vs. prenatal centre.
Down Syndrome
Comparison of combined, biochemical and nuchal translucency screening for Down's syndrome in first trimester in Northern Finland.
Down Syndrome
Comparison of First Trimester Screening for Down's Syndrome Using Free Beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein-A Levels between Spontaneous and IVF Pregnancies at 12 Weeks of Gestation.
Down Syndrome
Comparison of Nicolaides' risk evaluation for Down's syndrome with a novel software: an analysis of 1,463 cases.
Down Syndrome
Comparison of serum markers in first-trimester down syndrome screening.
Down Syndrome
Comparison of the new PRC software with the established algorithm of the FMF UK for the detection of trisomy 21 and 18/13.
Down Syndrome
Comparison of Three First Trimester Screening Algorithms for Trisomy 21 with and without Adjustment for Maternal Characteristics.
Down Syndrome
Comparison of two immunoassay systems for hCG? and PAPP-A in prenatal screening for trisomy 21, 18, and 13 in the first trimester.
Down Syndrome
Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
Down Syndrome
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Down Syndrome
Diagnosis of fetal acrania during the first trimester nuchal translucency screening for Down syndrome.
Down Syndrome
Diagnostic value of ultrasonographic combining biochemical markers for Down syndrome screening in first trimester: a meta-analysis.
Down Syndrome
Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13+6 weeks of gestation.
Down Syndrome
Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome.
Down Syndrome
Early first-trimester free beta-hCG and PAPP-A serum distributions in monochorionic and dichorionic twins.
Down Syndrome
Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency.
Down Syndrome
Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening.
Down Syndrome
Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
Down Syndrome
Effect of ethnicity on first trimester biomarkers for combined trisomy 21 screening: results from a multicenter study in six Asian countries.
Down Syndrome
Effect of fetal gender on first trimester markers and on Down syndrome screening.
Down Syndrome
Erroneous production of PAPP-A kits: the impact of a downward shift in PAPP-A concentration on the test performance of first-trimester combined screening for Down syndrome.
Down Syndrome
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Down Syndrome
Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures.
Down Syndrome
Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland.
Down Syndrome
Evaluation of indications for amniocentesis in cases of normal fetal ultrasound results.
Down Syndrome
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Down Syndrome
Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access(®) platform: suitability for use in first trimester Down's syndrome screening.
Down Syndrome
Fine-tuning ofroutine combined first- trimester screening: The ratio of serum-free- beta-human chorionic gonadotropin (f?-hCG) to pregnancy-associated plasma protein-A (PAPP-A) could improve performance of Down syndrome screening program, a retrospective cohort study in Iran.
Down Syndrome
First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.
Down Syndrome
First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
Down Syndrome
First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction.
Down Syndrome
First trimester combined screening for Trisomy 21 in Hong Kong: outcome of the first 10,000 cases.
Down Syndrome
First trimester combined screening for trisomy 21 with different combinations of placental growth factor, free ?-hCG and PAPP-A.
Down Syndrome
First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay.
Down Syndrome
First trimester Down syndrome screening: Distribution of markers and comparison of assays for quantification of pregnancy-associated plasma protein-A.
Down Syndrome
First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
Down Syndrome
First trimester increased nuchal translucency associated with fetal achondroplasia.
Down Syndrome
First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome.
Down Syndrome
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
Down Syndrome
First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies.
Down Syndrome
First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
Down Syndrome
First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free ?-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.
Down Syndrome
First trimester PAPP-A in the detection of non-Down syndrome aneuploidy.
Down Syndrome
First trimester predictors of adverse pregnancy outcomes.
Down Syndrome
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free beta-hCG and PAPP-A.
Down Syndrome
First trimester screening for aneuploidy: serum biochemical markers.
Down Syndrome
First trimester screening for Down syndrome using free beta hCG, total hCG and PAPP-A: an exploratory study.
Down Syndrome
First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-? human chorionic gonadotrophin, placental growth factor, and ?-fetoprotein.
Down Syndrome
First trimester screening for Down's syndrome after assisted reproductive technology: non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10-14 weeks of gestation.
Down Syndrome
First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness.
Down Syndrome
First trimester serum tests for Down's syndrome screening.
Down Syndrome
First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
Down Syndrome
First trimester uterine artery pulsatility index levels in euploid and aneuploid pregnancies.
Down Syndrome
First- and second-trimester evaluation of risk for Down syndrome.
Down Syndrome
First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
Down Syndrome
First-trimester biochemical screening for Down syndrome with the use of PAPP-A, AFP, and beta-hCG.
Down Syndrome
First-trimester biochemical screening for Down syndrome.
Down Syndrome
First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Down Syndrome
First-trimester combined screening for trisomy 21 in a predominantly Chinese population.
Down Syndrome
First-trimester combined screening is effective for the detection of unbalanced chromosomal translocations at 11 to 12 weeks of gestation.
Down Syndrome
First-trimester Down syndrome screening in women younger than 35 years old and cost-effectiveness analysis in Taiwan population.
Down Syndrome
First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
Down Syndrome
First-trimester Down syndrome screening: component analytes and timing for optimal performance.
Down Syndrome
First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.
Down Syndrome
First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss.
Down Syndrome
First-trimester maternal serum level of pregnancy-associated plasma protein-A is an independent predictor of fetal maxillary bone length.
Down Syndrome
First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies.
Down Syndrome
First-trimester screening for aneuploidy: research or standard of care?
Down Syndrome
First-trimester screening for chromosomal abnormalities.
Down Syndrome
First-trimester screening for Down syndrome in singleton pregnancies achieved by intrauterine insemination.
Down Syndrome
First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy--the combined test.
Down Syndrome
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Down Syndrome
First-trimester screening for trisomies in pregnancies with vanishing twin.
Down Syndrome
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Down Syndrome
First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
Down Syndrome
First-trimester screening for trisomy 21 using alpha-fetoprotein.
Down Syndrome
First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies.
Down Syndrome
First-trimester screening with nasal bone in twins.
Down Syndrome
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Down Syndrome
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Down Syndrome
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Down Syndrome
Frequency and clinical consequences of extremely high maternal serum PAPP-A levels.
Down Syndrome
Frontomaxillary facial angle at 11 + 0 to 13 + 6 weeks in Chinese population.
Down Syndrome
Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Down Syndrome
Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies.
Down Syndrome
Higher median levels of free beta-hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population.
Down Syndrome
Human chorionic gonadotropin and plasma protein-A in alpha0-thalassemia pregnancies.
Down Syndrome
Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell-free fetal DNA.
Down Syndrome
Immunoassay-Amplified Responses Using a Functionalized MoS2-Based SPR Biosensor to Detect PAPP-A2 in Maternal Serum Samples to Screen for Fetal Down's Syndrome.
Down Syndrome
Impact of replacing or adding placental growth factor on Down syndrome screening: A prospective cohort study.
Down Syndrome
Impact of the Maternal Age-Related Risk in First-Trimester Combined Screening for Trisomy 21.
Down Syndrome
Implementation of One-Stop-Clinic for Risk Assessment of chromosomal abnormalities in the first trimester, evaluating the effectiveness and making it part of our daily practice.
Down Syndrome
Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women.
Down Syndrome
Influence of first trimester biochemistry methodology on detection rate in screening for trisomy 21.
Down Syndrome
Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters.
Down Syndrome
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Down Syndrome
Interstitial pregnancy undetected during earlier first-trimester screening for fetal aneuploidy at 13 weeks' gestation.
Down Syndrome
Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
Down Syndrome
Longer time-to-pregnancy in spontaneously conceived pregnancies is associated with lower PAPP-A and free ?-hCG in first trimester screening for Down syndrome.
Down Syndrome
Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype.
Down Syndrome
Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks.
Down Syndrome
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Down Syndrome
Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester.
Down Syndrome
Maternal serum free ss-hCG and PAPP-A in patients with habitual abortion-influence on first-trimester screening for chromosomal abnormalities.
Down Syndrome
Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks.
Down Syndrome
Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies.
Down Syndrome
Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
Down Syndrome
Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester.
Down Syndrome
Maternal serum levels of placental proteins after in vitro fertilisation and their implications for prenatal screening.
Down Syndrome
Maternal serum levels of total activin-A in first-trimester trisomy 21 pregnancies.
Down Syndrome
Maternal serum placental growth factor and ?-fetoprotein testing in first trimester screening for Down syndrome.
Down Syndrome
Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies.
Down Syndrome
Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
Down Syndrome
Maternal serum pregnancy-associated plasma protein-A and free beta-human chorionic gonadotrophin in pregnancies conceived with fresh and frozen-thawed embryos from in vitro fertilization and intracytoplasmic sperm injection.
Down Syndrome
Maternal serum screening for fetal genetic disorders.
Down Syndrome
Maternal serum screening marker levels in women with a previous aneuploidy pregnancy.
Down Syndrome
Maternal serum soluble HLA-G in complicated pregnancies.
Down Syndrome
Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy.
Down Syndrome
Median levels of serum biomarkers of fetal Down syndrome detected during the first trimester among pregnant Thai women.
Down Syndrome
Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
Down Syndrome
Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol.
Down Syndrome
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Down Syndrome
Nasal bone in screening for T21 at 11-13 + 6 weeks of gestation - a multicenter study.
Down Syndrome
Normal range of intracranial translucency (IT) assessed by three-dimensional ultrasound at 11?+?0 to 13?+?6 weeks in a Chinese population.
Down Syndrome
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Down Syndrome
Observational study comparing the performance of first-trimester screening protocols for detecting trisomy 21 in a North Indian population.
Down Syndrome
One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
Down Syndrome
OP19.01: PAPP-A and beta-hCG as markers of low birth weight and preterm delivery in a consecutive cohort of 1867 pregnancies undergoing combined first trimester screening for Down syndrome.
Down Syndrome
Optimisation of sandwich ELISA based on monoclonal antibodies for the specific measurement of pregnancy-associated plasma protein (PAPP-A) in acute coronary syndrome.
Down Syndrome
Pattern of secretion of pregnancy-associated plasma protein-A (PAPP-A) during pregnancies complicated by fetal aneuploidy, in vivo and in vitro.
Down Syndrome
Performance of free beta-human chorionic gonadotrophin (free beta-hCG) and pregnancy associated plasma protein-A (PAPP-A) analysis between Delfia Xpress and AutoDelfia systems in The Netherlands.
Down Syndrome
PLAC4 and beta-HCG mRNA levels are not altered in the maternal circulation of pregnancies with trisomy 21.
Down Syndrome
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Down Syndrome
Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A: use in first-trimester screening for Down syndrome.
Down Syndrome
Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A.
Down Syndrome
Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome.
Down Syndrome
Pregnancy associated plasma protein-A2: a novel biomarker for Down syndrome.
Down Syndrome
Pregnancy outcome in the setting of extremely low first trimester PAPP-A levels.
Down Syndrome
Pregnancy-associated plasma protein A (PAPP-A), a first-trimester screening test for Down syndrome and other chromosomal anomalies.
Down Syndrome
Pregnancy-associated plasma protein A (PAPP-A): measurement by highly sensitive and specific enzyme immunoassay, importance of first-trimester serum determinations, and stability studies.
Down Syndrome
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Down Syndrome
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Down Syndrome
Pregnancy-associated plasma protein-E (PAPP-E).
Down Syndrome
Prenatal diagnosis of partial monosomy 2q (2q37.3?qter) and partial trisomy 10q (10q24.31?qter) of paternal origin associated with increased nuchal translucency and abnormal maternal serum screening results.
Down Syndrome
Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing.
Down Syndrome
Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies.
Down Syndrome
Prenatal screening in the first trimester of pregnancy.
Down Syndrome
Prenatal Screening Markers for Down Syndrome: Sensitivity, Specificity, Positive and Negative Expected Value Method.
Down Syndrome
Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.
Down Syndrome
Production and characterization of monoclonal antibodies against pregnancy-associated plasma protein A.
Down Syndrome
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Down Syndrome
Prospective study evaluating performance of first-trimester combined screening for trisomy 21 using repeat sampling of maternal serum markers PAPP-A and free ?-hCG.
Down Syndrome
Prospective validation of first-trimester combined screening for trisomy 21.
Down Syndrome
Quantification of proteolytically active pregnancy-associated plasma protein-A with an assay based on quenched fluorescence.
Down Syndrome
Re: First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free ?-human chorionic gonadotropin and pregnancy-associated plasma protein-A. K. O. Kagan, M. Hoopmann, H. Abele, R. Alkier and K. Lüthgens. Ultrasound Obstet Gynecol 2012; 40: 530-535.
Down Syndrome
Reference centile chart for fetal nuchal translucency, maternal serum PAPP-A and free beta hCG.
Down Syndrome
Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study.
Down Syndrome
Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population.
Down Syndrome
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Down Syndrome
Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
Down Syndrome
Screening for aneuploidy in first and second trimesters: is there an optimal paradigm?
Down Syndrome
Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.
Down Syndrome
Screening for Down's syndrome in early and late first and second trimester using six maternal serum markers.
Down Syndrome
Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters.
Down Syndrome
Screening for fetal aneuploidies at 11 to 13 weeks.
Down Syndrome
Screening for fetal trisomy 21 in gestational weeks 6 and 7.
Down Syndrome
Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Down Syndrome
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Down Syndrome
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Down Syndrome
Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
Down Syndrome
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Down Syndrome
Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness.
Down Syndrome
Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free beta-hCG or PAPP-A levels?
Down Syndrome
Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Down Syndrome
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Down Syndrome
Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18.
Down Syndrome
Second trimester two-step trisomy 18 screening using maternal serum markers.
Down Syndrome
Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Down Syndrome
Second-trimester maternal pregnancy-associated plasma protein a and inhibin a levels in fetal trisomies.
Down Syndrome
Sequential pathways of testing after first-trimester screening for trisomy 21.
Down Syndrome
Serum leptin in first-trimester Down syndrome pregnancies.
Down Syndrome
Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome.
Down Syndrome
Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy.
Down Syndrome
Serum PAPP-A measurements in first-trimester screening for Down syndrome.
Down Syndrome
SURUSS in perspective.
Down Syndrome
Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy.
Down Syndrome
The clinical usefulness of biochemical (free ?-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
Down Syndrome
The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Down Syndrome
The first-trimester screen in clinical practice.
Down Syndrome
The impact of bias in serum-free ?-hCG and PAPP-A MoM levels on first trimester screening for trisomy 21.
Down Syndrome
The impact of bias in the crown rump length measurement on first trimester screening for trisomy 21.
Down Syndrome
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Down Syndrome
The impact of fetal gender on first trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies.
Down Syndrome
The impact of temporal variability of biochemical markers PAPP-A and free beta-hCG on the specificity of the first-trimester Down syndrome screening: a Croatian retrospective study.
Down Syndrome
The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Down Syndrome
The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy.
Down Syndrome
The NTplus method of screening for Down syndrome: achieving the 2010 targets?
Down Syndrome
The relationship between environmental exposures and hormonal abnormalities in pregnant women: An epidemiological study in Yazd, Iran.
Down Syndrome
The use of nuchal translucency in contemporary obstetric practice.
Down Syndrome
The utility of circulating LHCGR as a predictor of Down's syndrome in early pregnancy.
Down Syndrome
Time-resolved immunofluorometric assay of pregnancy-associated plasma protein A in maternal serum screening for Down's syndrome in first trimester of pregnancy.
Down Syndrome
Total pregnancy-associated plasma protein A--a first trimester maternal serum marker for Down's syndrome: clinical and technical assessment of a poly-monoclonal enzyme immunoassay.
Down Syndrome
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Down Syndrome
Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Down Syndrome
Ultrasound and fetal diagnosis.
Down Syndrome
Undetectable pregnancy-associated plasma protein-A in antenatal serum Down's syndrome screening: a case of assay interference.
Down Syndrome
Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
Down Syndrome
Urinary hyperglycosylated hCG in first trimester screening for chromosomal abnormalities.
Down Syndrome
Will PAPP-A be a biochemical marker for screening of Down's syndrome in the first trimester?
Down Syndrome
[Clinical study of assessment of trisomy 21--precise risk evaluation in the first trimester of pregnancy]
Down Syndrome
[Cross-Validation of the First Trimester Screening Algorithm of the FMF London on 38 700 Pregnancies in Germany].
Down Syndrome
[Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research]
Down Syndrome
[Fetal erythroblasts from maternal blood for prenatal genetic diagnosis]
Down Syndrome
[Low PAPP-A levels between 11 and 13(+6) weeks of gestation and the risk of preeclampsia].
Down Syndrome
[Measurement of pregnancy-associated plasma protein A in maternal peripheral blood and Down syndrome]
Down Syndrome
[PAPP-A in the first trimester of pregnancy]
Down Syndrome
[Prenatal diagnosis of Down syndrome: study of correlations between two types of blood collection tubes].
Down Syndrome
[Prenatal risk calculation: comparison between Fast Screen pre I plus software and ViewPoint software. Evaluation of the risk calculation algorithms].
Down Syndrome
[Screening by maternal serum markers for Down's syndrome]
Dyslipidemias
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Eclampsia
Pregnancy-associated plasma protein A gene polymorphism in pregnant women with preeclampsia and intrauterine growth restriction.
Endometrial Neoplasms
Immunohistochemical localization of placental proteins and tumor-associated antigens in endometrial cancer and endometrial hyperplasia.
Endometriosis
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis.
Endometriosis
Increased pregnancy-associated plasma protein-A (PAPP-A) concentrations in peritoneal fluid of women with endometriosis.
Endometriosis
Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis.
Endometriosis
PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis.
Endometriosis
The endometrial response to chorionic gonadotropin is blunted in a baboon model of endometriosis.
Epilepsy
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Essential Hypertension
Associations of pregnancy-associated plasma protein-A level with essential hypertension and hypertensive disorders in pregnancy in Chinese population: a meta-analysis of 20 research studies involving 3332 individuals.
Fatty Liver
Genetic and Pharmacological Inhibition of PAPP-A Protects Against Visceral Obesity in Mice.
Fetal Death
Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome.
Fetal Death
Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome.
Fetal Death
Both Low and High PAPP-A Concentrations in the First Trimester of Pregnancy Are Associated with Increased Risk of Delivery before 32 Weeks in Twin Gestation.
Fetal Death
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Fetal Death
Does Low PAPP-A Predict Adverse Placenta-Mediated Outcomes in a Low-Risk Nulliparous Population? the Great Obstetrical Syndromes (GOS) Study.
Fetal Death
First-trimester screening for trisomies in pregnancies with vanishing twin.
Fetal Death
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Fetal Death
Obstetric Outcome in Pregnant Patients with Low Level of Pregnancy-Associated Plasma Protein A in First Trimester.
Fetal Death
RU 486 mediated leukocytic inflammatory reaction at the utero-placental interface.
Fetal Death
The role of trophoblast dysfunction in the aetiology of miscarriage.
Fetal Growth Retardation
ADAM12 and PAPP-A: Candidate regulators of trophoblast invasion and first trimester markers of healthy trophoblasts.
Fetal Growth Retardation
Are 1st-trimester ?-human chorionic gonadotrophin and pregnancy-associated plasma protein A levels predictive of intrapartum fetal compromise in a selected normal population?
Fetal Growth Retardation
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Fetal Growth Retardation
Association between fetal fraction on cell-free DNA testing and first trimester markers for pre-eclampsia.
Fetal Growth Retardation
Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome.
Fetal Growth Retardation
Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
Fetal Growth Retardation
Biochemical markers in screening for preeclampsia and intrauterine growth restriction.
Fetal Growth Retardation
Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
Fetal Growth Retardation
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Fetal Growth Retardation
Distinction between fetal growth restriction and small for gestational age newborn weight enhances the prognostic value of low PAPP-A in the first trimester.
Fetal Growth Retardation
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
Fetal Growth Retardation
Efficiency of first-trimester growth restriction and low pregnancy-associated plasma protein-A in predicting small for gestational age at delivery.
Fetal Growth Retardation
Evaluation of biochemical markers combined with uterine artery Doppler parameters in fetuses with growth restriction: a case-control study.
Fetal Growth Retardation
Evaluation of maternal and perinatal outcomes among overweight women who experienced stillbirth.
Fetal Growth Retardation
First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction.
Fetal Growth Retardation
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
Fetal Growth Retardation
First trimester pregnancy associated plasma protein-A as a marker for poor pregnancy outcome in patients with early-onset fetal growth restriction.
Fetal Growth Retardation
First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system.
Fetal Growth Retardation
First-trimester placental volume and vascularization measured by 3-dimensional power Doppler sonography in pregnancies with low serum pregnancy-associated plasma protein a levels.
Fetal Growth Retardation
First-trimester screening for fetal growth restriction using Doppler color flow analysis of the uterine artery and serum PAPP-A levels in unselected pregnancies.
Fetal Growth Retardation
First-trimester umbilical vein blood flow in pregnancies with low serum pregnancy-associated plasma protein-A levels: an early predictor of fetal growth restriction.
Fetal Growth Retardation
Identification of a prenatal profile of Cornelia de Lange syndrome (CdLS): A review of 53 CdLS pregnancies.
Fetal Growth Retardation
Is there a relationship between cord blood pregnancy-associated plasma protein-A and birth weight and length?
Fetal Growth Retardation
Low PAPP-A: the impact of ultrasound to evaluate fetal growth.
Fetal Growth Retardation
Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery.
Fetal Growth Retardation
Measurement of plasma placental proteins and estriol in the detection of intrauterine growth retardation.
Fetal Growth Retardation
New Predictive Model at 11+0 to 13+6 Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction.
Fetal Growth Retardation
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
Fetal Growth Retardation
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Fetal Growth Retardation
Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.
Fetal Growth Retardation
Predictive value of pregnancy-associated plasma protein-A (PAPP-A) and free beta-hCG on fetal growth restriction: results of a prospective study.
Fetal Growth Retardation
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Fetal Growth Retardation
Pregnancy-associated plasma protein A for prediction of fetal growth restriction.
Fetal Growth Retardation
Pregnancy-associated plasma protein A gene polymorphism in pregnant women with preeclampsia and intrauterine growth restriction.
Fetal Growth Retardation
Rare autosomal trisomies: Important and not so rare.
Fetal Growth Retardation
Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency.
Fetal Growth Retardation
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation.
Fetal Growth Retardation
Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies.
Fetal Growth Retardation
Second-trimester fetal growth as a predictor of poor obstetric and neonatal outcome in patients with low first-trimester serum pregnancy-associated plasma protein-A and a euploid fetus.
Fetal Growth Retardation
Significance of pregnancy-associated plasma protein A (PAPP-A) concentration determination in the assessment of final outcome of pregnancy.
Fetal Growth Retardation
Studies on the concentration of pregnancy-associated plasma protein-A during normal and complicated pregnancy.
Fetal Growth Retardation
The evaluating of pregnancy-associated plasma protein-A with the likelihood of small for gestational age.
Fetal Growth Retardation
The Impact of First-Trimester Serum Free beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein A on the Diagnosis of Fetal Growth Restriction and Small for Gestational Age Infant.
Fetal Growth Retardation
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
Fetal Growth Retardation
[Detection of pregnancy-specific beta 1-glycoproteins (SP1) and pregnancy-associated plasma protein A (PAPP-A) in maternal serum. Diagnostic significance in intrauterine fetal retardation]
Fetofetal Transfusion
A trend toward increased first trimester free beta-hCG and PAPP-A in monochorionic twins complicated by Twin-to-Twin Transfusion syndrome.
Galactosemias
Cryopreservation of ovarian tissue may be considered in young girls with galactosemia.
Gastroschisis
Frequency and clinical consequences of extremely high maternal serum PAPP-A levels.
Genetic Diseases, Inborn
Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse.
Glucose Intolerance
Incorporating first trimester analytes to predict delivery of a large for gestational infant in women with impaired glucose tolerance.
Glucose Intolerance
PAPP-A concentrations change in patients with gestational diabetes.
Granulosa Cell Tumor
Insulin-like growth factor, insulin-like growth factor-binding protein-4, and pregnancy-associated plasma protein-A gene expression in human granulosa cell tumors.
Headache Disorders
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Heart Defects, Congenital
First trimester combined screening biochemistry in detection of congenital heart defects.
Heart Diseases
Detection of multiple cardiac markers with an integrated acoustic platform for cardiovascular risk assessment.
Heart Diseases
Pregnancy-associated plasma protein A and mortality in haemodialysis.
Heart Diseases
Pregnancy-associated plasma protein A in non-cardiac conditions.
Heart Diseases
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Heart Failure
Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.
Heart Failure
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Heart Failure
Serum pregnancy-associated plasma protein a in patients with heart failure.
Heart Septal Defects, Ventricular
First trimester combined screening biochemistry in detection of congenital heart defects.
HELLP Syndrome
PAPP-A levels of late pregnancy in preeclampsia and HELLP syndrome.
Hepatitis B
Effect of Maternal Hepatitis B Carrier Status on First-Trimester Markers of Down Syndrome.
Hirsutism
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
HIV Infections
Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
HIV Infections
Pregnancy-associated plasma protein-a is associated with subclinical atherosclerosis in men with HIV infection.
Hydatidiform Mole
Placenta-associated plasma protein-A (PAPP-A, SP4) in trophoblastic tumours.
Hydatidiform Mole
Pregnancy-associated protein-A does not improve predictability of pregnancy success or failure over human chorionic gonadotropin levels in early normal and abnormal pregnancy.
Hydatidiform Mole
Progesterone dependence and extratrophoblastic origin of pregnancy-associated plasma protein-A (PAPP-A) in early pregnancy.
Hydatidiform Mole
Prognostic significance of the new placental proteins in trophoblastic disease.
Hydatidiform Mole
The contribution of maternal serum markers in the early prenatal diagnosis of molar pregnancies.
Hydatidiform Mole, Invasive
Placenta-associated plasma protein-A (PAPP-A, SP4) in trophoblastic tumours.
Hypercholesterolemia
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Hypercholesterolemia
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Hypercholesterolemia
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Hyperemesis Gravidarum
First trimester maternal serum PAPP-A and free ?-HCG levels in hyperemesis gravidarum.
Hyperemesis Gravidarum
Maternal serum pregnancy-associated plasma protein-A levels in hyperemesis gravidarum: a prospective case control study.
Hyperglycemia
PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.
Hyperlipidemias
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Hypertension
Are first-trimester ultrasound features prior to 11?weeks' gestation and maternal factors able to predict maternal hypertensive disorders?
Hypertension
Association of calcium channel blocker use and pregnancy-associated plasma protein-A among older adults with hypertension: results from the ilSIRENTE study.
Hypertension
Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study.
Hypertension
Association of first-trimester low PAPP-A levels with preterm birth.
Hypertension
Associations of plasma PAPP-A2 and genetic variations with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults.
Hypertension
Cardiac Biomarkers and Cardiovascular Outcome in Children with Chronic Kidney Disease.
Hypertension
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Hypertension
Development and Validation of a Risk Factor Scoring System for First-Trimester Prediction of Preeclampsia.
Hypertension
Early prediction of hypertension during pregnancy in a low-resource setting.
Hypertension
Early Pregnancy Maternal Serum PAPP-A and Urinary Protein-Creatinine Ratio as Predictive Markers of Pregnancy Induced Hypertension.
Hypertension
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
Hypertension
First trimester PAPP-A levels associated with early prediction of pregnancy induced hypertension.
Hypertension
First trimester PAPP-A2, PAPP-A and hCG? in small-for-gestational-age pregnancies.
Hypertension
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
Hypertension
First-trimester prediction of hypertensive disorders in pregnancy.
Hypertension
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Hypertension
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Hypertension
MoM cutoffs for variables, an important tool for multivariate analysis and accurate interpretation of preeclampsia risk in high-risk pregnancy at 11-13(+6) weeks gestation.
Hypertension
Placental and circulating pregnancy-associated plasma protein A concentrates in normal and pathological term pregnancies.
Hypertension
Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free ?-hCG.
Hypertension
Predictive value of combined serum biomarkers for adverse pregnancy outcomes.
Hypertension
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Hypertension
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.
Hypertension
Role of maternal factors, PAPP-A, and Doppler in screening for early- and late-onset pregnancy hypertension in Asian population.
Hypertension
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Hypertension
Ultrasound placental image texture analysis using artificial intelligence to predict hypertension in pregnancy.
Hypertension, Pregnancy-Induced
A prospective study of screening for hypertensive disorders of pregnancy at 11-13 weeks in a Scandinavian population.
Hypertension, Pregnancy-Induced
Association of pregnancy-associated plasma protein A and vascular endothelial growth factor with pregnancy-induced hypertension.
Hypertension, Pregnancy-Induced
Biochemical Markers for Prediction of Hypertensive Disorders of Pregnancy.
Hypertension, Pregnancy-Induced
Correlation between First-Trimester Maternal Serum Markers, Second-Trimester Uterine Artery Doppler Indices and Pregnancy Outcome.
Hypertension, Pregnancy-Induced
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Hypertension, Pregnancy-Induced
Early Pregnancy Maternal Serum PAPP-A and Urinary Protein-Creatinine Ratio as Predictive Markers of Pregnancy Induced Hypertension.
Hypertension, Pregnancy-Induced
Early Pregnancy-Associated Plasma Protein A Concentrations are Associated with Third Trimester Insulin Sensitivity.
Hypertension, Pregnancy-Induced
Efficacy of combined medication of nifedipine and magnesium sulfate on gestational hypertension and the effect on PAPP-A, VEGF, NO, Hcy and vWF.
Hypertension, Pregnancy-Induced
Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks.
Hypertension, Pregnancy-Induced
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
Hypertension, Pregnancy-Induced
First trimester PAPP-A levels associated with early prediction of pregnancy induced hypertension.
Hypertension, Pregnancy-Induced
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
Hypertension, Pregnancy-Induced
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Hypertension, Pregnancy-Induced
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
Hypertension, Pregnancy-Induced
Improved prediction of gestational hypertension by inclusion of placental growth factor and pregnancy associated plasma protein-a in a sample of Ghanaian women.
Hypertension, Pregnancy-Induced
Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Hypertension, Pregnancy-Induced
Obstetrical complications associated with abnormal maternal serum markers analytes.
Hypertension, Pregnancy-Induced
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Infant, Newborn, Diseases
PAPP-A and free ?-hCG in relation to admission to neonatal intensive care unit and neonatal disease.
Infections
Combined first-trimester Down syndrome screening in HIV-infected women.
Infections
First and Second Trimester Markers of Fetal Aneuploidy in Pregnant Women with HIV Infection.
Infections
Pregnancy-Associated Plasma Protein A as an Independent Mortality Predictor in Long-Term Hemodialysis Patients.
Infections
Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.
Infections
[Inflammation in atherosclerosis]
Infertility
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis.
Infertility
First trimester screening for Down's syndrome after assisted reproductive technology: non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10-14 weeks of gestation.
Infertility
Increased pregnancy-associated plasma protein-A (PAPP-A) concentrations in peritoneal fluid of women with endometriosis.
Infertility
Longer time-to-pregnancy in spontaneously conceived pregnancies is associated with lower PAPP-A and free ?-hCG in first trimester screening for Down syndrome.
Inflammatory Bowel Diseases
The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis.
Insulin Resistance
Early Pregnancy-Associated Plasma Protein A Concentrations are Associated with Third Trimester Insulin Sensitivity.
Insulin Resistance
Female PAPP-A knockout mice are resistant to metabolic dysfunction induced by high-fat/high-sucrose feeding at middle age.
Insulin Resistance
Metabolic consequences of pregnancy-associated plasma protein-A deficiency in mice: exploring possible relationship to the longevity phenotype.
Insulin Resistance
Novel Modulators of the Growth Hormone - Insulin-Like Growth Factor Axis: Pregnancy-Associated Plasma Protein-A2 and Stanniocalcin-2.
Insulin Resistance
PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans.
Insulin Resistance
Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density.
Intervertebral Disc Degeneration
The relationship between pregnancy-associated plasma protein-A (PAPP-A) and human intervertebral disc degeneration.
Ischemic Attack, Transient
Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease.
Ischemic Stroke
Association of pregnancy-associated plasma protein-A gene polymorphism with ischemic stroke in northern Chinese Han population.
Ischemic Stroke
Correlation of plasma soluble cluster of differentiation 40 ligand, alpha fetoprotein A, and pregnancy-associated plasma protein A with carotid plaque in patients with ischemic stroke.
Ischemic Stroke
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Ischemic Stroke
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Ischemic Stroke
Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease.
Ischemic Stroke
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Ischemic Stroke
The prognostic value of serum pregnancy-associated plasma protein A, S100 and high sensitivity C-reactive protein in acute ischemic stroke patients without heparin administration.
Kidney Diseases
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Kidney Failure, Chronic
Association of E-Selectin Gene Polymorphism and Serum PAPP-A with Carotid Atherosclerosis in End-Stage Renal Disease.
Kidney Failure, Chronic
PAPP-A in cardiac and non-cardiac conditions.
Kidney Failure, Chronic
Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities.
Leiomyoma
Identification of genes with higher expression in human uterine leiomyomas than in the corresponding myometrium.
Lung Diseases
Insulin-Like Growth Factor Bioactivity, Stanniocalcin-2, Pregnancy-Associated Plasma Protein-A, and IGF-Binding Protein-4 in Pleural Fluid and Serum From Patients With Pulmonary Disease.
Lung Injury
Epithelial lining fluid free IGF-I-to-PAPP-A ratio is associated with bronchopulmonary dysplasia in preterm infants.
Lung Neoplasms
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Lung Neoplasms
IGFBP-4: A promising biomarker for lung cancer.
Lung Neoplasms
PAPP-A and cancer.
Lung Neoplasms
Pregnancy-Associated Plasma Protein-A2 Is Associated With Mortality in Patients With Lung Cancer.
Lung Neoplasms
Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo.
Lung Neoplasms
Relationship between pregnancy-associated plasma protein-A and lung cancer.
Lymphangioma, Cystic
First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Lymphangioma, Cystic
Rare chromosomal abnormalities: Can they be identified using conventional first trimester combined screening methods?
Malnutrition
Serum pregnancy-associated plasma protein A correlates with inflammation and malnutrition in patients treated with maintenance hemodialysis.
Mastocytosis
Distinct plasma biomarkers confirm the diagnosis of mastocytosis and identify increased risk of anaphylaxis.
Melanoma
Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.
Mesothelioma
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Mesothelioma, Malignant
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Metabolic Diseases
Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo.
Metabolic Syndrome
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
Microcephaly
Prenatal diagnosis and molecular cytogenetic characterization of de novo pure partial trisomy 6p associated with microcephaly, craniosynostosis and abnormal maternal serum biochemistry.
Migraine Disorders
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Migraine with Aura
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
MINOCA
Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.
Multicystic Dysplastic Kidney
Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two-vessel cord, and hydrocele.
Multiple Sclerosis
The clinical course of multiple sclerosis during pregnancy and the puerperium.
Myocardial Infarction
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Myocardial Infarction
Biomarkers for early detection of risk in female patients with coronary artery disease: pilot study.
Myocardial Infarction
Circulating pregnancy-associated plasma protein A is not an early marker of acute myocardial infarction.
Myocardial Infarction
Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation.
Myocardial Infarction
Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation.
Myocardial Infarction
Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients.
Myocardial Infarction
Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein a assays for triage of patients with acute myocardial infarction.
Myocardial Infarction
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Myocardial Infarction
Examination of serum pregnancy-associated plasma protein A clinical value in acute coronary syndrome prediction and monitoring.
Myocardial Infarction
Free vs Total Pregnancy-Associated Plasma Protein A (PAPP-A) as a Predictor of 1-Year Outcome in Patients Presenting with Non-ST-Elevation Acute Coronary Syndrome.
Myocardial Infarction
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Myocardial Infarction
Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.
Myocardial Infarction
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Myocardial Infarction
Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction.
Myocardial Infarction
Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy.
Myocardial Infarction
Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.
Myocardial Infarction
PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI.
Myocardial Infarction
PAPP-A: a possible pathogenic link to the instability of atherosclerotic plaque.
Myocardial Infarction
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
Myocardial Infarction
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Myocardial Infarction
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Myocardial Infarction
Pregnancy-associated plasma protein A (PAPP-A) for the early diagnosis of myocardial infarction: More doubts than certainties.
Myocardial Infarction
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Myocardial Infarction
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Myocardial Infarction
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Myocardial Infarction
Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: Use of a new monoclonal antibody-based assay.
Myocardial Infarction
Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI).
Myocardial Infarction
Pregnancy-associated plasma protein A: Has this biomarker crossed the boundary from research to clinical practice?
Myocardial Infarction
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Myocardial Infarction
Pregnancy-associated plasma protein-a, a marker for outcome in patients suspected for acute coronary syndrome.
Myocardial Infarction
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina.
Myocardial Infarction
Relationship between Serum Levels of Pregnancy Associated Plasma Protein A and Coronary Artery Disease in Males.
Myocardial Infarction
Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes.
Myocardial Infarction
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
Myocardial Infarction
Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration.
Myocardial Infarction
The activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-elevation myocardial infarction: a brief communication.
Myocardial Infarction
The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction.
Myocardial Infarction
The long-term prognostic value of multiple biomarkers following a myocardial infarction.
Myocardial Infarction
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
Myocardial Infarction
Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome.
Myocardial Infarction
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Myocardial Ischemia
Markers for early detection of cardiac diseases.
Myocardial Ischemia
Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.
Myocardial Ischemia
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Neoplasm Metastasis
Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
Neoplasm Metastasis
Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.
Neoplasm Metastasis
Pregnancy-associated plasma protein a in cancer: expression, oncogenic functions and regulation.
Neoplasm Metastasis
Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
Neoplasm Metastasis
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
Neoplasms
A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts.
Neoplasms
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Neoplasms
Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes.
Neoplasms
Annulus cells from more degenerated human discs show modified gene expression in 3D culture compared with expression in cells from healthier discs.
Neoplasms
Association of endocannabinoids with pain in endometriosis.
Neoplasms
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Neoplasms
Bikunin target genes in ovarian cancer cells identified by microarray analysis.
Neoplasms
Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NF?B Signaling in Hepatocellular Carcinoma.
Neoplasms
Characterization of the common fragile site FRA9E and its potential role in ovarian cancer.
Neoplasms
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis.
Neoplasms
CRP and TNF-???induce PAPP-A expression in human peripheral blood mononuclear cells.
Neoplasms
Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol.
Neoplasms
Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells.
Neoplasms
Early pregnancy reference intervals; 29 serum analytes from 4 to 12 weeks' gestation in naturally conceived and uncomplicated pregnancies resulting in live births.
Neoplasms
Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.
Neoplasms
F2-isoprostanes in kidney transplant patients: relationship with inflammatory markers.
Neoplasms
Female PAPP-A knockout mice are resistant to metabolic dysfunction induced by high-fat/high-sucrose feeding at middle age.
Neoplasms
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
Neoplasms
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Neoplasms
Identification and characterization of renal cell carcinoma gene markers.
Neoplasms
Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells.
Neoplasms
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Neoplasms
IGFBP-4 and PAPP-A in normal physiology and disease.
Neoplasms
IGFBP-4: A promising biomarker for lung cancer.
Neoplasms
Insulin-like growth factor, insulin-like growth factor-binding protein-4, and pregnancy-associated plasma protein-A gene expression in human granulosa cell tumors.
Neoplasms
Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy
Neoplasms
Is pregnancy-associated plasma protein A a tumor marker?
Neoplasms
Lactation opposes pappalysin-1-driven pregnancy-associated breast cancer.
Neoplasms
Longevity and Age-Related Pathology of Mice Deficient in Pregnancy-Associated Plasma Protein-A.
Neoplasms
Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Neoplasms
miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.
Neoplasms
Molecular regulation of the IGF-binding protein-4 protease system in human fibroblasts: identification of a novel inducible inhibitor.
Neoplasms
Motor and memory testing of long-lived pregnancy-associated plasma protein--a knock-out mice.
Neoplasms
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Neoplasms
Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation.
Neoplasms
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Neoplasms
Overexpression of pregnancy-associated plasma protein-a in ovarian cancer cells promotes tumor growth in vivo.
Neoplasms
PAPP-A and cancer.
Neoplasms
PAPP-A functions as a tumor suppressor and is downregulated in renal cell carcinoma.
Neoplasms
PAPP-A in cardiac and non-cardiac conditions.
Neoplasms
PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.
Neoplasms
PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma.
Neoplasms
Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.
Neoplasms
Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.
Neoplasms
Placental proteins in male serum.
Neoplasms
Posttransplant inflammation associated with onset of chronic kidney disease.
Neoplasms
Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.
Neoplasms
Preferential expression of PAPPA in human preadipocytes from omental fat.
Neoplasms
Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.
Neoplasms
Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Neoplasms
Pregnancy-associated plasma protein a in cancer: expression, oncogenic functions and regulation.
Neoplasms
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Neoplasms
Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
Neoplasms
Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
Neoplasms
Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells.
Neoplasms
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
Neoplasms
Pregnancy-Associated Plasma Protein-A Accelerates Atherosclerosis by Regulating Reverse Cholesterol Transport and Inflammation.
Neoplasms
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Neoplasms
Pregnancy-associated plasma protein-A expression in human breast cancer.
Neoplasms
Pregnancy-Associated Plasma Protein-A2 Is Associated With Mortality in Patients With Lung Cancer.
Neoplasms
Pretransplant inflammation: a risk factor for delayed graft function?
Neoplasms
Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events.
Neoplasms
Production of pregnancy-associated plasma protein-A (PAPP-A) by cultured tumour granulosa cells.
Neoplasms
Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.
Neoplasms
Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo.
Neoplasms
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
Neoplasms
Regulation of pregnancy-associated plasma protein-A expression in cultured human osteoblasts.
Neoplasms
Review: immunomodulatory activity of pregnancy-associated plasma protein-A.
Neoplasms
Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus.
Neoplasms
The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning.
Neoplasms
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Neoplasms
Whole-genome reconstruction and mutational signatures in gastric cancer.
Neoplasms
[Effects of C-reactive protein and tumor necrosis factor-alpha on mRNA expression of pregnancy-associated plasma protein-A in monocytes]
Neoplasms
[Expression and activity of proteases in metastasis of ovarian cancer].
Neoplasms
[Inflammation in atherosclerosis]
Neoplasms
[Inflammation markers and risk stratification in patients with acute coronary syndromes: design of the SIESTA Study (Systemic Inflammation Evaluation in Patients with non-ST segment elevation Acute coronary syndromes)]
Neoplasms
[Pregnancy proteins]
Neoplasms
[Relationship between the expression levels of PAPP-A metalloproteinase and growth and transcriptional factors in endometrial cancer].
Neoplasms, Germ Cell and Embryonal
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Neural Tube Defects
Diagnosis of fetal acrania during the first trimester nuchal translucency screening for Down syndrome.
Neural Tube Defects
Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
Non-ST Elevated Myocardial Infarction
A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity.
Obesity
Female PAPP-A knockout mice are resistant to metabolic dysfunction induced by high-fat/high-sucrose feeding at middle age.
Obesity
Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation.
Obesity
Preferential expression of PAPPA in human preadipocytes from omental fat.
Obesity, Abdominal
Genetic and Pharmacological Inhibition of PAPP-A Protects Against Visceral Obesity in Mice.
Obesity, Abdominal
Preferential Impact of Pregnancy Associated Plasma Protein-A Deficiency on Visceral Fat in Mice on High Fat Diet.
Obstetric Labor, Premature
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Obstetric Labor, Premature
Late pregnancy associated plasma protein A levels decrease in preterm labor.
Obstetric Labor, Premature
Low maternal serum levels of pregnancy-associated plasma protein-A during the first trimester are associated with subsequent preterm delivery with preterm premature rupture of membranes.
Obstetric Labor, Premature
PAPP-A levels as an early marker of idiopathic preterm birth: a pilot study.
Obstetric Labor, Premature
Relationship Between Pregnancy Complications and Serum Pregnancy Associated-Plasma-Protein-A and Free-?-Human Chorionic Gonadotropin in the First Trimester Among Iranian Women.
Obstetric Labor, Premature
The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study.
Oligohydramnios
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Oligohydramnios
Is pregnancy associated plasma protein-A (PAPP-A) a marker for adverse perinatal outcomes in preterm isolated oligohydramnios cases?
Oligohydramnios
Ultrasound and circulating placental protein measurements in complications of early pregnancy.
Oligospermia
Measurement of the pregnancy-associated proteins, placental protein 14 and pregnancy-associated plasma protein A in human seminal plasma.
Osteoporosis
Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo.
Osteosarcoma
Covalent interaction between proform of eosinophil major basic protein (proMBP) and pregnancy-associated plasma protein-A (PAPP-A) is a cell-mediated event and required for proMBP inhibition of the catalytic activity of PAPP-A.
Osteosarcoma
Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro.
Ovarian Diseases
Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle.
Ovarian Neoplasms
A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts.
Ovarian Neoplasms
Characterization of the common fragile site FRA9E and its potential role in ovarian cancer.
Ovarian Neoplasms
Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
Ovarian Neoplasms
Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy
Ovarian Neoplasms
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Ovarian Neoplasms
Overexpression of pregnancy-associated plasma protein-a in ovarian cancer cells promotes tumor growth in vivo.
Ovarian Neoplasms
Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells.
pappalysin-1 deficiency
Adult height and long-term outcomes after rhIGF-1 therapy in two patients with PAPP-A2 deficiency.
pappalysin-1 deficiency
Comparative gene expression and phenotype analyses of skeletal muscle from aged wild-type and PAPP-A-deficient mice.
pappalysin-1 deficiency
Disorders caused by genetic defects associated with GH-dependent genes: PAPPA2 defects.
pappalysin-1 deficiency
Genetics of Growth Disorders-Which Patients Require Genetic Testing?
pappalysin-1 deficiency
Inducible knock out of pregnancy-associated plasma protein-a gene expression in the adult mouse: effect on vascular injury response.
pappalysin-1 deficiency
Inhibition of longevity regulator PAPP-A modulates tissue homeostasis via restraint of mesenchymal stromal cells.
pappalysin-1 deficiency
Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation.
pappalysin-1 deficiency
Metabolic consequences of pregnancy-associated plasma protein-A deficiency in mice: exploring possible relationship to the longevity phenotype.
pappalysin-1 deficiency
Metabolomics changes in patients with PAPP-A2 deficiency in response to rhIGF1 treatment.
pappalysin-1 deficiency
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
pappalysin-1 deficiency
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
pappalysin-1 deficiency
Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density.
pappalysin-1 deficiency
Preferential Impact of Pregnancy Associated Plasma Protein-A Deficiency on Visceral Fat in Mice on High Fat Diet.
pappalysin-1 deficiency
Pregnancy Associated Plasma Protein A2 (PAPP-A2) Affects Bone Size and Shape and Contributes to Natural Variation in Postnatal Growth in Mice.
pappalysin-1 deficiency
Pregnancy-associated plasma protein-A deficiency improves survival of mice on a high fat diet.
pappalysin-1 deficiency
Pregnancy-associated plasma protein-A2 (PAPP-A2): tissue expression and biological consequences of gene knockout in mice.
pappalysin-1 deficiency
rhIGF-1 Treatment Increases Bone Mineral Density and Trabecular Bone Structure in Children with PAPP-A2 Deficiency.
pappalysin-1 deficiency
Short stature with low insulin-like growth factor 1 availability due to pregnancy-associated plasma protein A2 deficiency in a Saudi family.
pappalysin-1 deficiency
Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling.
pappalysin-1 deficiency
Treatment with recombinant human insulin-like growth factor-I improves growth in patients with PAPP-A2 deficiency.
Pediatric Obesity
Pregnancy-associated plasma protein A (PAPP-A) in obese children: relation to markers and risk factors of atherosclerosis, and members of the IGF system.
Pelvic Infection
Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.
Periapical Periodontitis
The importance of inflammatory biomarkers, IL-6 and PAPP-A, in the evaluation of asymptomatic apical periodontitis.
Pericardial Effusion
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women.
Perinatal Death
First trimester pregnancy associated plasma protein-A as a marker for poor pregnancy outcome in patients with early-onset fetal growth restriction.
Peripheral Arterial Disease
Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study.
Peripheral Arterial Disease
Pregnancy-associated plasma protein-A as a marker for long-term mortality in patients with peripheral atherosclerosis: inconclusive findings from the Linz Peripheral Arterial Disease (LIPAD) study.
Peripheral Vascular Diseases
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Peripheral Vascular Diseases
Gender-Related Differences in Patients Presenting with Suspected Acute Coronary Syndromes: Clinical Presentation, Biomarkers and Diagnosis.
Placenta Accreta
Elevated first trimester PAPP-A is associated with increased risk of placenta accreta.
Placenta Accreta
First trimester serum PAPP-A is associated with placenta accreta: a retrospective study.
Placenta Accreta
Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
Placenta Accreta
[Prognostic significance of specific proteins of pregnancy in women with a uterine scar and placenta accreta.]
Placenta Previa
First trimester serum PAPP-A is associated with placenta accreta: a retrospective study.
Placenta Previa
Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
Placental Insufficiency
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
Placental Insufficiency
The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome.
Placental Insufficiency
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
Pleural Effusion
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Pneumonia
Prognostic value of serum pregnancy-associated plasma protein A level at the initial ED presentation in elderly patients with CAP.
Polycystic Kidney Diseases
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
Polycystic Kidney, Autosomal Dominant
Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
Polycystic Ovary Syndrome
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum and follicular fluid levels of IGF-II, IGF-binding protein-4 and pregnancy-associated plasma protein-A in controlled ovarian hyperstimulation cycle between polycystic ovarian syndrome (PCOS) and non-PCOS women.
Polyhydramnios
Identification of a prenatal profile of Cornelia de Lange syndrome (CdLS): A review of 53 CdLS pregnancies.
Pre-Eclampsia
?hCG and PAPP-A in First Trimester: Predictive Factors for Preeclampsia?
Pre-Eclampsia
A prospective study of screening for hypertensive disorders of pregnancy at 11-13 weeks in a Scandinavian population.
Pre-Eclampsia
A robust immunoassay for pregnancy-associated plasma protein-A2 based on analysis of circulating antigen: establishment of normal ranges in pregnancy.
Pre-Eclampsia
ADAM 12 and PAPP-A at 14-17 weeks' gestation as biomarkers of pre-eclampsia.
Pre-Eclampsia
ADAM12 and PAPP-A: Candidate regulators of trophoblast invasion and first trimester markers of healthy trophoblasts.
Pre-Eclampsia
ADAM12s in maternal serum as a potential marker of pre-eclampsia.
Pre-Eclampsia
Adverse pregnancy outcome in patients with low pregnancy-associated plasma protein-A: The Indian Experience.
Pre-Eclampsia
Angiogenic and antiangiogenic factors in preeclampsia.
Pre-Eclampsia
Application of metabolomics to preeclampsia diagnosis.
Pre-Eclampsia
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Pre-Eclampsia
Are Women with a History of Low PAPP-A at Risk for Adverse Perinatal Outcomes in a Subsequent Pregnancy?
Pre-Eclampsia
Assessment of ?-human-derived chorionic gonadotrophic hormone (?hCG) and pregnancy-associated plasma protein A (PAPP-A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: a cohort study.
Pre-Eclampsia
Association between fetal fraction on cell-free DNA testing and first trimester markers for pre-eclampsia.
Pre-Eclampsia
Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications.
Pre-Eclampsia
Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome.
Pre-Eclampsia
Association of pregnancy-associated plasma protein A polymorphism with preeclampsia - a pilot study.
Pre-Eclampsia
Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis.
Pre-Eclampsia
Biochemical Markers for Prediction of Hypertensive Disorders of Pregnancy.
Pre-Eclampsia
Biochemical markers in screening for preeclampsia and intrauterine growth restriction.
Pre-Eclampsia
Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
Pre-Eclampsia
Biomarkers in pre-eclampsia: A novel approach to early detection of the disease.
Pre-Eclampsia
Can first trimester placental protein-13 and pregnancy-associated plasma protein-A predict pre-eclampsia in Turkish women?
Pre-Eclampsia
CircRNA-0004904, CircRNA-0001855, and PAPP-A: Potential Novel Biomarkers for the Prediction of Preeclampsia.
Pre-Eclampsia
Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy.
Pre-Eclampsia
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
Pre-Eclampsia
Combination of PAPPA, fhCG?, AFP, PlGF, sTNFR1, and Maternal Characteristics in Prediction of Early-onset Preeclampsia.
Pre-Eclampsia
Comparison of preeclampsia and fetal growth restriction screenings at first trimester in a high-risk population.
Pre-Eclampsia
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
Pre-Eclampsia
Competing-risks model for prediction of small-for-gestational-age neonates from maternal characteristics, serum PAPP-A and PlGF at 11-13?weeks' gestation.
Pre-Eclampsia
Concentration of pregnancy-associated plasma protein A (PAPP-A) in patients with pre-eclamptic toxaemia.
Pre-Eclampsia
Could first-trimester assessment of placental functions predict preeclampsia and intrauterine growth restriction? A prospective cohort study.
Pre-Eclampsia
Could mean platelet volume in late first trimester of pregnancy predict intrauterine growth restriction and pre-eclampsia?
Pre-Eclampsia
Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients.
Pre-Eclampsia
Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption.
Pre-Eclampsia
Development and Validation of a Risk Factor Scoring System for First-Trimester Prediction of Preeclampsia.
Pre-Eclampsia
Differential expression of human placental PAPP-A2 over gestation and in preeclampsia.
Pre-Eclampsia
Does the Addition of Serum PAPP-A and ?-hCG Improve the Predictive Value of Uterine Artery Pulsatility Index for Preeclampsia at 11-14 Weeks of Gestation? A Prospective Observational Study.
Pre-Eclampsia
Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity.
Pre-Eclampsia
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
Pre-Eclampsia
Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study.
Pre-Eclampsia
Early Prognostic Factors for the Progress of Preeclampsia - Our Experience in the Period 2010-2011.
Pre-Eclampsia
Early-Onset Severe Preeclampsia by First Trimester Pregnancy-Associated Plasma Protein A and Total Human Chorionic Gonadotropin (Podcast).
Pre-Eclampsia
Early-Onset Severe Preeclampsia by First Trimester Pregnancy-Associated Plasma Protein A and Total Human Chorionic Gonadotropin.
Pre-Eclampsia
Effect of routine first trimester combined screening for pre-eclampsia on small for gestational age birth: a secondary interrupted time series analysis.
Pre-Eclampsia
Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia.
Pre-Eclampsia
Evaluation of fetal hypermethylated RASSF1A in pre-eclampsia and its relationship with placental protein-13, pregnancy associated plasma protein-A and urine protein.
Pre-Eclampsia
Evaluation of maternal and perinatal outcomes among overweight women who experienced stillbirth.
Pre-Eclampsia
Evaluation of serum ?-hCG and PAPP-A levels in pregnant women at risk of developing preeclampsia.
Pre-Eclampsia
Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT.
Pre-Eclampsia
Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks.
Pre-Eclampsia
First trimester combined screening test for aneuploidies in anti-Ro carriers pregnant women.
Pre-Eclampsia
First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction.
Pre-Eclampsia
First trimester maternal serum PIGF, free ?-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia.
Pre-Eclampsia
First trimester origins of fetal growth impairment.
Pre-Eclampsia
First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia.
Pre-Eclampsia
First trimester PAPP-A2, PAPP-A and hCG? in small-for-gestational-age pregnancies.
Pre-Eclampsia
First trimester pregnancy-associated plasma protein A and human chorionic gonadotropin-beta in early and late pre-eclampsia.
Pre-Eclampsia
First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia.
Pre-Eclampsia
First trimester screening of late-onset preeclampsia in a low risk and low volume obstetrical setting.
Pre-Eclampsia
First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia.
Pre-Eclampsia
First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study.
Pre-Eclampsia
First- and second-trimester maternal serum markers of pre-eclampsia in twin pregnancy.
Pre-Eclampsia
First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis.
Pre-Eclampsia
First-trimester 3-dimensional power Doppler placental vascularization indices from the whole placenta versus the placental bed to predict preeclampsia: does pregnancy-associated plasma protein a or uterine artery Doppler sonography help?
Pre-Eclampsia
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
Pre-Eclampsia
First-Trimester Levels of Pregnancy-Associated Plasma Protein A2 (PAPP-A2) in the Maternal Circulation Are Elevated in Pregnancies That Subsequently Develop Preeclampsia.
Pre-Eclampsia
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Pre-Eclampsia
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
Pre-Eclampsia
First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia.
Pre-Eclampsia
First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia.
Pre-Eclampsia
First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia.
Pre-Eclampsia
First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia.
Pre-Eclampsia
First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume.
Pre-Eclampsia
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Pre-Eclampsia
First-Trimester Uterine Artery Pulsatility Index and Maternal Serum PAPP-A and PlGF in Prediction of Preeclampsia in Primigravida.
Pre-Eclampsia
Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia.
Pre-Eclampsia
Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell-free fetal DNA.
Pre-Eclampsia
Impact of Endometriomas and Deep Infiltrating Endometriosis on Pregnancy Outcomes and on First and Second Trimester Markers of Impaired Placentation.
Pre-Eclampsia
Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study.
Pre-Eclampsia
Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients.
Pre-Eclampsia
Low First Trimester Pregnancy-Associated Plasma Protein-A Levels Are Not Associated with an Increased Risk of Intrapartum Fetal Compromise or Adverse Neonatal Outcomes: A Retrospective Cohort Study.
Pre-Eclampsia
Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
Pre-Eclampsia
Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes.
Pre-Eclampsia
Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia.
Pre-Eclampsia
Lower placental growth factor and higher free ?-hCG and PAPP-A levels in the fetal circulation of near-term pregnancies complicated with severe preeclampsia.
Pre-Eclampsia
Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia.
Pre-Eclampsia
Maternal hemodynamics in screen positive and negative women of the ASPRE trial.
Pre-Eclampsia
Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Pre-Eclampsia
Maternal Serum Adiponectin at 11-13 Weeks of Gestation in Preeclampsia.
Pre-Eclampsia
Maternal Serum Human Placental Growth Hormone (hPGH) at 11 to 13 Weeks of Gestation in Preeclampsia.
Pre-Eclampsia
Maternal serum PAPP-A and free ß-hCG at 12, 22, 32 weeks' gestation in screening for pre-eclampsia.
Pre-Eclampsia
Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study.
Pre-Eclampsia
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free ?-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Pre-Eclampsia
Maternal Serum PLGF, PAPPA, ?-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia.
Pre-Eclampsia
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Pre-Eclampsia
Maternal Serum S100-B, PAPP-A and IL-6 levels in severe preeclampsia.
Pre-Eclampsia
New Predictive Model at 11+0 to 13+6 Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction.
Pre-Eclampsia
Novel cardiovascular biomarkers in women with a history of early preeclampsia.
Pre-Eclampsia
Obstetric Outcome in Pregnant Patients with Low Level of Pregnancy-Associated Plasma Protein A in First Trimester.
Pre-Eclampsia
OS039. Early prediction of preeclampsia with maternal parameters,SVEGF-R1, PLGF, Inhibin-A and PAPP-A in general population: Results from the MSPE study.
Pre-Eclampsia
OS087. Maternal characteristics, mean arterial pressure and PLGF in early prediction of preeclampsia.
Pre-Eclampsia
PAPP-A levels of late pregnancy in preeclampsia and HELLP syndrome.
Pre-Eclampsia
PAPP-A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia.
Pre-Eclampsia
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
Pre-Eclampsia
Performance of the FMF First-Trimester Preeclampsia-Screening Algorithm in a High-Risk Population in The Netherlands.
Pre-Eclampsia
Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia.
Pre-Eclampsia
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Pre-Eclampsia
Plasma mRNA concentrations of placenta-specific 1 (PLAC1) and pregnancy associated plasma protein A (PAPP-A) are higher in early-onset than late-onset pre-eclampsia.
Pre-Eclampsia
PP13 and PAPP-A in the First and Second Trimesters: Predictive Factors for Preeclampsia?
Pre-Eclampsia
Pre-eclampsia screening in the first trimester - preemptive action to prevent the peril.
Pre-Eclampsia
Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free ?-hCG.
Pre-Eclampsia
Prediction and prevention of pre-eclampsia in Asian subpopulation.
Pre-Eclampsia
Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.
Pre-Eclampsia
Prediction of first-trimester preeclampsia: Relevance of the oxidative stress marker MDA in a combination model with PP-13, PAPP-A and beta-HCG.
Pre-Eclampsia
Prediction of pre-eclampsia and its subtypes in high-risk cohort: hyperglycosylated human chorionic gonadotropin in multivariate models.
Pre-Eclampsia
Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation.
Pre-Eclampsia
Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13?weeks' gestation: data from EVENTS trial.
Pre-Eclampsia
Prediction of Preeclampsia by First Trimester Combined Test and Simple Complete Blood Count Parameters.
Pre-Eclampsia
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler.
Pre-Eclampsia
Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
Pre-Eclampsia
Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19-24 weeks.
Pre-Eclampsia
Predictive value of combined serum biomarkers for adverse pregnancy outcomes.
Pre-Eclampsia
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Pre-Eclampsia
Pregnancy-associated and placental proteins in the placental tissue of normal pregnant women and patients with pre-eclampsia at term.
Pre-Eclampsia
Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia.
Pre-Eclampsia
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Pre-Eclampsia
Pregnancy-associated plasma protein A gene polymorphism in pregnant women with preeclampsia and intrauterine growth restriction.
Pre-Eclampsia
Pregnancy-associated plasma protein a polymorphisms in patients with risk pregnancies.
Pre-Eclampsia
Pregnancy-associated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester.
Pre-Eclampsia
Prospective evaluation of the first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China.
Pre-Eclampsia
Pulsatility index in combination with biomarkers or mean arterial pressure for the prediction of pre-eclampsia: Systematic literature review and meta-analysis.
Pre-Eclampsia
Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
Pre-Eclampsia
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Pre-Eclampsia
Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
Pre-Eclampsia
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation.
Pre-Eclampsia
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Pre-Eclampsia
Screening for pre-eclampsia by maternal factors and biomarkers at 11-13?weeks' gestation.
Pre-Eclampsia
Screening for preeclampsia in low-risk twin pregnancies at early gestation.
Pre-Eclampsia
Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women.
Pre-Eclampsia
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Pre-Eclampsia
Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies.
Pre-Eclampsia
Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia.
Pre-Eclampsia
Serum Inhibin-A and PAPP-A2 in the prediction of pre-eclampsia during the first and second trimesters in high-risk women.
Pre-Eclampsia
Serum Levels of Angiogenic Factors Distinguish Between Women with Preeclampsia and Normotensive Pregnant Women But Not Severity of Preeclampsia in an Obstetric Center in Turkey.
Pre-Eclampsia
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Pre-Eclampsia
Significance of pregnancy-associated plasma protein A (PAPP-A) concentration determination in the assessment of final outcome of pregnancy.
Pre-Eclampsia
The potential role of pregnancy-associated plasma protein-A2 in angiogenesis and development of preeclampsia.
Pre-Eclampsia
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
Pre-Eclampsia
The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study.
Pre-Eclampsia
The role of maternal serumbeta-HCG and PAPP-A levels at gestational weeks 10 to 14 in the prediction of pre-eclampsia.
Pre-Eclampsia
The utility of first trimester uterine artery Doppler, placental volume and PAPP-A levels alone and in combination to predict preeclampsia.
Pre-Eclampsia
The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia.
Pre-Eclampsia
Use of first or second trimester serum markers, or both, to predict preeclampsia.
Pre-Eclampsia
Use of FMF algorithm for prediction of preeclampsia in high risk pregnancies: a single center longitudinal study.
Pre-Eclampsia
Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study.
Pre-Eclampsia
Uteroplacental Ischemia Is Associated with Increased PAPP-A2.
Pre-Eclampsia
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
Pre-Eclampsia
Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin.
Pre-Eclampsia
[Low PAPP-A levels between 11 and 13(+6) weeks of gestation and the risk of preeclampsia].
Pregnancy Complications
Both Low and High PAPP-A Concentrations in the First Trimester of Pregnancy Are Associated with Increased Risk of Delivery before 32 Weeks in Twin Gestation.
Pregnancy Complications
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
Pregnancy Complications
First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy.
Pregnancy Complications
First trimester pregnancy-associated plasma protein-A in pregnancies complicated by subsequent gestational diabetes.
Pregnancy Complications
Increased time-to-pregnancy and first trimester Down's syndrome screening.
Pregnancy Complications
PAPP-A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia.
Pregnancy Complications
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
Pregnancy Complications
Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A.
Pregnancy Complications
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler.
Pregnancy Complications
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Pregnancy Complications
The influence of parity and gravidity on first trimester markers of chromosomal abnormality.
Pregnancy Complications
[Prediction of adverse pregnancy outcome by first-trimester maternal serum PAPP-A]
Pregnancy, Ectopic
Accuracy of single measurements of pregnancy-associated plasma protein-A, human chorionic gonadotropin and progesterone in the diagnosis of early pregnancy failure.
Pregnancy, Ectopic
Are pregnancy-associated plasma protein-A (PAPP-A) and CA 125 measurements after IVF-ET possible predictors of early pregnancy wastage?
Pregnancy, Ectopic
Circulating and tissue concentrations of pregnancy-associated plasma protein-A (PAPP-A) in tubal ectopic gestation.
Pregnancy, Ectopic
Circulating levels of pregnancy-associated plasma protein-A (PAPP-A) and human chorionic gonadotrophin (hCG) in intrauterine and extrauterine pregnancies.
Pregnancy, Ectopic
Corpus luteum failure in ectopic pregnancy.
Pregnancy, Ectopic
Predicting first trimester pregnancy outcome: derivation of a multiple marker test.
Pregnancy, Ectopic
Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.
Pregnancy, Ectopic
Pregnancy-associated plasma protein A in pregnancy-related gynaecologic emergency.
Pregnancy, Ectopic
The disappearance rate of pregnancy-associated plasma protein-A (PAPP-A) after the end of normal and abnormal pregnancies.
Pregnancy, Ectopic
The value of vascular endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages.
Pregnancy, High-Risk
Is pregnancy associated plasma protein-A (PAPP-A) a marker for adverse perinatal outcomes in preterm isolated oligohydramnios cases?
Pregnancy, High-Risk
Placental volume and vascularization flow indices by 3D power Doppler US using VOCAL technique and correlation with IGF-1, free beta-hCG, PAPP-A, and uterine artery Doppler at 11-14 weeks of pregnancy.
Pregnancy, Tubal
Circulating and tissue concentrations of pregnancy-associated plasma protein-A (PAPP-A) in tubal ectopic gestation.
Pregnancy, Tubal
The prediction of pregnancy failure by measurement of pregnancy-associated plasma protein A (PAPP-A) following in vitro fertilization and embryo transfer.
Premature Birth
Adverse pregnancy outcome in patients with low pregnancy-associated plasma protein-A: The Indian Experience.
Premature Birth
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Premature Birth
Association of first-trimester low PAPP-A levels with preterm birth.
Premature Birth
Association of first-trimester pregnancy-associated plasma protein A levels and idiopathic preterm delivery: A population-based screening study.
Premature Birth
Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis.
Premature Birth
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
Premature Birth
Confined placental mosaicism revisited: Impact on pregnancy characteristics and outcome.
Premature Birth
Correlation of first-trimester serum levels of pregnancy-associated plasma protein A with small-for-gestational-age neonates and preterm births.
Premature Birth
Decreased First-trimester Maternal Serum Free-beta Subunit Human Chorionic Gonadotropin and Preterm Birth in Twin Gestations.
Premature Birth
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
Premature Birth
First trimester pregnancy associated plasma protein-A as a marker for poor pregnancy outcome in patients with early-onset fetal growth restriction.
Premature Birth
First-trimester maternal serum biomarkers and the risk of cerebral palsy.
Premature Birth
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
Premature Birth
First-trimester prediction of preterm birth using ADAM12, PAPP-A, uterine artery Doppler, and maternal characteristics.
Premature Birth
First-trimester serum biomarker screening for fetal Down syndrome as a predictor of preterm delivery: a population-based study.
Premature Birth
First-trimester serum PAPP-A and f?-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome.
Premature Birth
Late pregnancy associated plasma protein A levels decrease in preterm labor.
Premature Birth
Low First Trimester Pregnancy-Associated Plasma Protein-A Levels Are Not Associated with an Increased Risk of Intrapartum Fetal Compromise or Adverse Neonatal Outcomes: A Retrospective Cohort Study.
Premature Birth
PAPP-A levels as an early marker of idiopathic preterm birth: a pilot study.
Premature Birth
Prediction of preterm birth in nulliparous women using logistic regression and machine learning.
Premature Birth
Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study.
Premature Birth
The predictive value of 18 and 22 week uterine artery Doppler in patients with low first trimester maternal serum PAPP-A.
Premature Birth
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
Premature Birth
The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study.
Premature Birth
Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study.
Premature Birth
Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes.
Premature Birth
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
Proteinuria
First trimester PAPP-A2, PAPP-A and hCG? in small-for-gestational-age pregnancies.
Proteinuria
Obstetrical complications associated with abnormal maternal serum markers analytes.
Proteinuria
PAPP-A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia.
Proteinuria
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Proteinuria
Pregnancy-associated plasma protein-A: evaluation of a new biomarker in renal transplant patients.
Psoriasis
Can pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?
Psoriasis
Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients.
Puberty, Precocious
Genomic association for sexual precocity in beef heifers using pre-selection of genes and haplotype reconstruction.
Pulmonary Disease, Chronic Obstructive
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Pulmonary Disease, Chronic Obstructive
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Pulmonary Disease, Chronic Obstructive
THE ROLE OF LIPOPROTEIN (A) AND PREGNANCY ASSOCIATED PLASMA PROTEIN A IN DIAGNOSTICS CORONARY HEART DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
Pulmonary Embolism
Diagnostic usefulness of pregnancy-associated plasma protein-A in suspected pulmonary embolism.
Pulmonary Embolism
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Pyelectasis
Genetic sonography after first-trimester Down syndrome screening.
Pyelectasis
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women.
Renal Insufficiency
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
Renal Insufficiency, Chronic
Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease.
Renal Insufficiency, Chronic
Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Renal Insufficiency, Chronic
Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) - intra- and inter-individual variability in chronic hemodialysis patients.
Renal Insufficiency, Chronic
Pregnancy-associated plasma protein A as a predictor of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a meta-analysis of prospective studies.
Renal Insufficiency, Chronic
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Respiratory Distress Syndrome
Can first trimester pregnancy-associated plasma protein-A predict the surfactant needs of preterm neonates?
Respiratory Distress Syndrome
The utility of pregnancy associated plasma protein-A MoM values in prediction of term respiratory distress syndrome.
Retinal Vein Occlusion
Increased pregnancy-associated plasma protein A in retinal vein occlusion.
Rhinitis, Allergic
Does pregnancy-associated plasma protein A have a role in allergic rhinitis?
Sarcoma, Ewing
EWS-FLI-1 creates a cell surface microenvironment conducive to IGF signaling by inducing pappalysin-1.
Sarcoma, Ewing
PAPP-A and cancer.
Sarcoma, Ewing
Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.
Sarcoma, Ewing
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
Sarcoma, Ewing
The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning.
Seminoma
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Sepsis
Elevated pregnancy-associated plasma protein A predicts myocardial dysfunction and death in severe sepsis.
Severe Combined Immunodeficiency
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Single Umbilical Artery
Comparison of fetal weight distribution improved by paternal height by Spanish standard versus Intergrowth 21st standard.
Single Umbilical Artery
The effects of isolated single umbilical artery on first and second trimester aneuploidy screening test parameters.
Sleep Apnea, Obstructive
The Relation between Pregnancy-Associated Plasma Protein A and Obstructive Sleep Apnea Syndrome.
Spondylitis, Ankylosing
Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors.
ST Elevation Myocardial Infarction
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
ST Elevation Myocardial Infarction
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
ST Elevation Myocardial Infarction
Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI).
ST Elevation Myocardial Infarction
Relationship between Serum Levels of Pregnancy Associated Plasma Protein A and Coronary Artery Disease in Males.
ST Elevation Myocardial Infarction
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
ST Elevation Myocardial Infarction
The activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-elevation myocardial infarction: a brief communication.
ST Elevation Myocardial Infarction
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
ST Elevation Myocardial Infarction
Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome.
Stillbirth
Adverse Fetal outcome: Is first trimester ultrasound and Doppler better predictor than biomarkers?
Stillbirth
Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome.
Stillbirth
Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study.
Stillbirth
Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
Stillbirth
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
Stillbirth
Does first-trimester serum pregnancy-associated plasma protein A differ in pregnant women with sickle cell disease?
Stillbirth
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
Stillbirth
First trimester origins of fetal growth impairment.
Stillbirth
First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis.
Stillbirth
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
Stillbirth
First-trimester placentation and the risk of antepartum stillbirth.
Stillbirth
First-trimester serum PAPP-A and f?-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome.
Stillbirth
Low maternal PAPP-A is associated with small-for-gestational age newborns and stillbirths.
Stillbirth
Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes.
Stillbirth
Placental growth factor in prediction of stillbirths at 11-13 weeks.
Stillbirth
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Stillbirth
Prediction and prevention of recurrent stillbirth.
Stillbirth
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Stillbirth
Prediction of stillbirth from placental growth factor at 11-13 weeks.
Stillbirth
Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome.
Stillbirth
Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study.
Stillbirth
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
Stillbirth
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
Stomach Neoplasms
Whole-genome reconstruction and mutational signatures in gastric cancer.
Stroke
Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study.
Stroke
Maternal hemodynamic assessment by USCOM® device in the first trimester of pregnancy.
Stroke
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Stroke
The prognostic value of serum pregnancy-associated plasma protein A, S100 and high sensitivity C-reactive protein in acute ischemic stroke patients without heparin administration.
Stroke
[THE CLINICAL LABORATORY MARKERS OF ATHEROSCLEROSIS IN PATIENTS WITH ATHEROTHROMBOTIC STROKE].
Tension-Type Headache
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Teratoma
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Testicular Neoplasms
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Tetralogy of Fallot
First trimester combined screening biochemistry in detection of congenital heart defects.
Thrombophilia
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Thrombophilia
The impact of inherited thrombophilia on first trimester combined aneuploidy screening test parameters.
Thrombosis
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Thrombosis
Evaluation of Serum Pregnancy Associated Plasma Protein-A & Plasma D-Dimer in Acute Coronary Syndrome.
Thyroid Neoplasms
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Thyroid Nodule
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Toxemia
Placental and circulating pregnancy-associated plasma protein A concentrates in normal and pathological term pregnancies.
Toxemia
[Fluctuations in pregnancy-associated protein A (PAPP-A) levels in the sera of pregnant women]
Tricuspid Valve Insufficiency
First Trimester Screening for Chromosomal Abnormalities by Integrated Application of Nuchal Translucency, Nasal Bone, Tricuspid Regurgitation, Ductus Venosus Flow Combined with Maternal Serum Free ?-HCG and PAPP-A: A 5-Year Prospective Study.
Tricuspid Valve Insufficiency
First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
Tricuspid Valve Insufficiency
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women.
Tricuspid Valve Insufficiency
Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV.
Tricuspid Valve Insufficiency
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Trisomy 13 Syndrome
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Trisomy 13 Syndrome
Aneuploidy screening in the first trimester.
Trisomy 13 Syndrome
First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies.
Trisomy 13 Syndrome
First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free ?-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.
Trisomy 13 Syndrome
First trimester PAPP-A in the detection of non-Down syndrome aneuploidy.
Trisomy 13 Syndrome
Maternal serum placental protein 13 at eleven to thirteen weeks in chromosomally abnormal pregnancies.
Trisomy 13 Syndrome
Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
Trisomy 13 Syndrome
Maternal serum screening marker levels in women with a previous aneuploidy pregnancy.
Trisomy 13 Syndrome
Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV.
Trisomy 13 Syndrome
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Trisomy 13 Syndrome
Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Trisomy 13 Syndrome
Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Trisomy 13 Syndrome
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Trisomy 18 Syndrome
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Trisomy 18 Syndrome
ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy.
Trisomy 18 Syndrome
Aneuploidy screening in the first trimester.
Trisomy 18 Syndrome
Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency.
Trisomy 18 Syndrome
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
Trisomy 18 Syndrome
First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies.
Trisomy 18 Syndrome
First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
Trisomy 18 Syndrome
First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies.
Trisomy 18 Syndrome
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Trisomy 18 Syndrome
Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies.
Trisomy 18 Syndrome
Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women.
Trisomy 18 Syndrome
Is ultrasound alone enough for prenatal screening of trisomy 18? A single centre experience in 69 cases over 10 years.
Trisomy 18 Syndrome
Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks.
Trisomy 18 Syndrome
Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies.
Trisomy 18 Syndrome
Maternal serum pregnancy-associated plasma protein A (PAPP-A) but not pregnancy-specific beta1-glycoprotein (SP1) is a useful second-trimester marker for fetal trisomy 18.
Trisomy 18 Syndrome
Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
Trisomy 18 Syndrome
Maternal serum screening for trisomy 18 in the first trimester of pregnancy.
Trisomy 18 Syndrome
Pregnancy-associated plasma protein-A truncation limits in antenatal screening for trisomy 18.
Trisomy 18 Syndrome
Prenatal diagnosis of 5p deletion syndrome: Report of five cases.
Trisomy 18 Syndrome
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Trisomy 18 Syndrome
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Trisomy 18 Syndrome
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Trisomy 18 Syndrome
Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18.
Trisomy 18 Syndrome
Second trimester two-step trisomy 18 screening using maternal serum markers.
Trisomy 18 Syndrome
Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Trisomy 18 Syndrome
Serum marker truncation limits in first trimester antenatal screening for trisomy 18.
Trisomy 18 Syndrome
The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (?-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
Trisomy 18 Syndrome
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Trisomy 18 Syndrome
Ultrasound and fetal diagnosis.
Trisomy 18 Syndrome
[First-Trimester Screening for Trisomies 18 and 13 with the Combined Use of the Risk Algorithms for Trisomy 21, 18 and 13.]
Trophoblastic Neoplasms
Is pregnancy-associated plasma protein A a tumor marker?
Turner Syndrome
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Turner Syndrome
Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester.
Turner Syndrome
The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies.
Turner Syndrome
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Uterine Hemorrhage
Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
Uterine Hemorrhage
Comparison of serum and urine hCG levels with SP1 and PAPP-A levels in patients with first-trimester vaginal bleeding.
Uterine Hemorrhage
Does vaginal bleeding influence first-trimester markers for Down syndrome?
Uterine Hemorrhage
Early vaginal bleeding and first-trimester markers for Down syndrome.
Uterine Hemorrhage
Pregnancy-associated plasma protein A in the prediction of early pregnancy failure.
Uterine Hemorrhage
Ultrasound and circulating placental protein measurements in complications of early pregnancy.
Uterine Hemorrhage
Value of Schwangerschaftsprotein 1 (SP1) and pregnancy-associated plasma protein-A (PAPP-A) in the clinical management of threatened abortion.
Vascular Diseases
Elevated serum levels of pregnancy-associated plasma protein-A in type 2 diabetics compared to healthy controls: associations with subclinical atherosclerosis parameters.
Vascular Diseases
Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
Vascular System Injuries
Constitutive expression of pregnancy-associated plasma protein-A in arterial smooth muscle reduces the vascular response to injury in vivo.
Vascular System Injuries
Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol.
Vascular System Injuries
Inducible knock out of pregnancy-associated plasma protein-a gene expression in the adult mouse: effect on vascular injury response.
Vascular System Injuries
Pregnancy-associated plasma protein A: Has this biomarker crossed the boundary from research to clinical practice?
Vascular System Injuries
Targeted disruption of the pregnancy-associated plasma protein-A gene is associated with diminished smooth muscle cell response to insulin-like growth factor-I and resistance to neointimal hyperplasia after vascular injury.
Venous Thrombosis
Increased pregnancy-associated plasma protein A in retinal vein occlusion.
Vitamin D Deficiency
Association between maternal circulating 25 hydroxyvitamin D concentration and placental volume in the first trimester.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3.4.24.79 pappalysin-1
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
